

*Expenditure
and
Prescriptions
Twelve Months
to
30 June 2017*

*PBS Information Management Section
Pricing and Policy Branch
Technology Assessment and Access Division*

This publication and previous editions can be accessed via the internet:
<http://www.pbs.gov.au/info/browse/statistics>

Please direct enquiries about this publication or requests for complimentary copies via:

Surface mail: Director
PBS Information Management Section
Pricing and Policy Branch, MDP 900
Department of Health
GPO Box 9848 Canberra ACT 2601

E-mail: pbsstats@health.gov.au

Production: Rasalinkam Seeniyar, Catherine Wilkinson

Acknowledgments:

Thanks to the following staff for their help in the access and provision of data and information used in this report: Sonja Davis, David Nott, Jane Ranson-Smith, Alison Mo, Chris Parker, Christopher Lee

Important Information

Unless otherwise indicated this publication has been produced using data provided to the Department of Health by the Department of Human Services. The figures reported in this publication relate to the value (benefit) or volume of PBS prescriptions that have been processed by the Department of Human Services. They refer only to paid services processed for prescription submitted and claimed via the PBS Online claiming system by the approved suppliers. They do not include any manually paid claims.

PBS Expenditure includes the following patient categories:

- General - Non-Safety Net (Ordinary)
- General - Safety Net
- Concessional - Non-Safety Net (Ordinary)
- Concessional - Safety Net
- Doctor's Bag

The patient category refers to the patient's eligibility status at the time of supply of the benefit. General patients hold a Medicare card, Concessional patients hold a Medicare card and one of the following cards from Centrelink:

- Pension Concession Card
- Commonwealth Seniors Health Card
- Health Care Card

There are two safety net thresholds – one for General patients and the other for Concessional patients.

From 1 January 2017, the general patient safety net threshold was **\$ 1,494.90**. When patients and/or their families reached this amount, they could apply for a Safety Net Card and pay only **\$6.30** per prescription for the rest of the calendar year. The concessional safety net threshold was **\$378.00**. Once patients and/or their families reached this amount, they could apply for a Safety Net Entitlement Card and receive items free of charge for the rest of the calendar year.

The Patient Contribution, Total Cost and Average Price amounts do not include brand or therapeutic premiums.

Caution should be exercised in referring to the breakdown by patient category in Table 23(a) on page 30 and Table 23(b) on page 32, because of a past problem in data supplied by the Department of Human Services whereby a number of General Safety Net scripts were wrongly allocated to Concessional Non-Safety Net. This problem has been fixed for 2008-09, but the 2006-07 and 2007-08 allocations of scripts and expenditure by patient category were inaccurate and not strictly comparable to the corresponding 2008-09 and later years' numbers.

The Department of Health has taken every care to ensure the data supplied is accurate but does not warrant that the data is error free and does not accept any liability for errors or omissions in the data.

Summary of Pharmaceutical Benefits Scheme 2016-2017

Total Pharmaceutical Benefits Scheme (PBS) government expenditure (both Section 85 and Section 100) on an accrual accounting basis for the 2016-2017 financial year was **\$12,058 million** (excluding revenue), compared with **\$10,838 million** for the previous year. This is an increase of **11.3%**.

The majority of the Expenditure and Prescriptions Report refers to PBS Section 85 data reported by date of supply.

The 2016-17 total volume of PBS Section 85 prescriptions decreased by **4.0%** to a total of **195.8 million**, compared to 203.9 million for the 2015-16 financial year.

The 2016-17 PBS Section 85 Government expenditure amounted to **\$8,729.2 million** (excluding rebates) which was **86.7%** of the total cost of PBS prescriptions. The remainder was patient contributions that amounted to **\$1,338.6 million**.

The majority of government expenditure in 2016-17 on PBS Section 85 prescriptions was directed towards concessional cardholders (**\$6,520.3 million, 74.7% of the total**), compared to concessional cardholders expenditure for 2015-16 (**\$6,081.7 million, 75.6%** of the total).

The average dispensed price (Patient contribution plus Government cost) per prescription of PBS Section 85 subsidised medicines increased to **\$51.45** in 2016-17, compared to **\$46.15** in 2015-16. The average government cost of these scripts was **\$44.58** for 2016-17, compared to \$39.45 for 2015-16.

Note: The 2016-17 publication is based on the date that the prescription medicine was supplied to the patient. Previous publications were based on the date that the claim was processed (and the payment finalised) by the Department of Human Services. The historical data from 1991-92 to 2015-16 on pages 30 to 34 remains by date of processing.

PBS Expenditure and Prescriptions 2016-17

INDEX

Table Label	Description	Page ##
Table 1(a)	PBS Expenditure on Accrual Accounting Basis, 2015-16 and 2016-17	1
Table 1(b)	PBS Section 100 Programmes on Accrual Accounting Basis, 2015-16 and 2016-17	1
Table 2(a)	PBS Section 85 Subsidised Prescriptions , 2015-16 and 2016-17	2
Table 2(b)	PBS Section 85 Government Cost, 2015-16 and 2016-17	2
Table 2(c)	RPBS Section 85 Subsidised Prescriptions , 2015-16 and 2016-17	2
Table 2(d)	RPBS Section 85 Government Cost, 2015-16 and 2016-17	2
Table 3(a)	PBS Subsidised Prescriptions, Government Cost, Patient Contribution and Average Price, 2016-17	3
Table 3(b)	PBS Subsidised Prescriptions, Government Cost, Patient Contribution and Average Price by Monthly Summary, 2015-16 and 2016-17	3
Table 4	PBS Subsidised Prescriptions by Pharmacy State, 2016-17	4
Table 5(a)	Top 50 PBS Drugs (Generic Name) Sorted by Highest Government Cost, 2016-17	5
Table 5(b)	Top 50 PBS Drugs (Generic Name) Sorted by Highest Subsidised Prescriptions, 2016-17	6
Table 6(a)	Top 50 PBS Items Codes Sorted by Highest Government Cost, 2016-17	7
Table 6(b)	Top 50 PBS Items Codes Sorted by Highest Subsidised Prescriptions, 2016-17	8
Table 7	Top 50 ATC Level 2 Drug Groups Sorted by Highest Total Prescription Volume, 2016-17	9
Table 8	Top 50 Drugs (Generic Name) Sorted by Highest Total Prescription Volume, 2016-17	10
Table 9	Top 50 PBS Item Codes Sorted by Highest Total Prescription Volume, 2016-17	11
Table 10	ATC Main Groups Comparison for PBS Subsidised Prescriptions, Government Cost, Patient Contribution and Average Price changes, 2015-16 and 2016-17	12
Table 11(a)	Top 35 Drugs Sorted by Highest Change to Government Cost, 2015-16 and 2016-17	13
Table 11(b)	Top 35 Drugs Sorted by Highest Change to Script Volume, 2015-16 and 2016-17	14
Table 12(a)	PBS Prescription Volume, 2013-14 to 2016-17	15
Table 12(b)	PBS expenditure, 2013-14 to 2016-17	15
Table 13	PBS Subsidised Prescriptions and Government Cost by Formulary, 2016-17	16
Table 14(a)	Top 20 Responsible Persons by Total Cost, 2016-17	17
Table 14(b)	Top 20 Responsible Persons by PBS Subsidised Prescriptions, 2016-17	18
Table 15	Number of Approved Community Pharmacies and Dispensing Doctors, 30 June 2017	19
Table 16	PBS Special Patient Contribution, 2016-17	19
Table 17(a)	PBS/RPBS prescriptions dispensed by Community Pharmacies, 2016-17	20
Table 17(b)	PBS/RPBS prescriptions by Discount Range dispensed by Community Pharmacies, 2016-17	20

PBS Expenditure and Prescriptions 2016-17

Table 18(a)	PBS/RPBS Continued Dispensing Medicines Prescriptions by dispensing Pharmacy State/Territory, 2016-17	21
Table 18(b)	PBS/RPBS Continued Dispensing Medicines Government Cost by dispensing Pharmacy State/Territory, 2016-17	21
Supplement 1	Community Pharmacy Agreement (CPA) Expenses	
Table 19	Remuneration for Community Pharmacies and Friendly Societies, 2016-17	22
Table 20	CPA Professional Pharmacy Programmes Expenditure, 2016-17	23
Table 21	Actual Costs of Major Components of CPA, 2016-17	24
Table 22	Community Services Obligation (CSO) Expenditure, 2016-17	24
Supplement 2	PBS Information Line Report, 2016-17	25-27
Supplement 3	National Diabetes Services Scheme (NDSS)	28-29
Supplement 4	Historical PBS Prescriptions and Expenditure	
Table 23(a)	Historical Pharmaceutical Benefits Scheme Prescriptions (1948-49 to 2016-17)	30-31
Table 23(b)	Historical Pharmaceutical Benefits Scheme Expenditure (1948-49 to 2016-17)	32-34

PBS Expenditure and Prescriptions 2016-17

Table 1(a): PBS Expenditure on Accrual Accounting Basis, 2015-16 and 2016-17

Category	2015-16	Percentage of Total	2016-17	Percentage of Total	Change	Change Percentage
Section 85 - Concessional	\$ 6,172,196,919	56.9%	\$ 6,716,569,270	55.7%	\$ 544,372,351	8.8%
Section 85 - General	\$ 1,912,963,069	17.7%	\$ 2,176,675,514	18.1%	\$ 263,712,445	13.8%
Doctors' Bag	\$ 17,218,481	0.2%	\$ 18,906,365	0.2%	\$ 1,687,884	9.8%
Section 100*	\$ 2,724,933,327	25.1%	\$ 3,135,750,822	26.0%	\$ 410,817,495	15.1%
Safety Net Cards	\$ 10,673,298	0.1%	\$ 9,721,956	0.1%	-\$ 951,343	-8.9%
Total	\$ 10,837,985,095	100.0%	\$ 12,057,623,927	100.0%	\$ 1,219,638,833	11.3%
Total Including Revenue**	\$ 10,143,081,604		\$ 8,790,109,229			

*Individual S100 programmes are shown in Table 1(b).

**The basis for reporting PBS revenue has changed between 2015-16 and 2016-17, and this means that Total Including Revenue cannot be compared between 2015-16 and 2016-17. The change in reporting PBS Revenue in 2016-17 brings this report into line with PBS revenue as reported in the Department of Health Annual Report. However to remain consistent with last year's Expenditure and Prescriptions report, 2015-16 Total Including Revenue has not been adjusted.

Table 1(b): PBS Section 100 Programmes on Accrual Accounting Basis, 2015-16 and 2016-17

Category	2015-16	Percentage of Total	2016-17	Percentage of Total	Change	Change Percentage
Highly Specialised Drugs	\$ 1,583,754,673	58.1%	\$ 1,910,193,161	60.9%	\$ 326,438,487	20.6%
Chemotherapy (EFC & CPAP)	\$ 702,421,712	25.8%	\$ 795,050,090	25.4%	\$ 92,628,379	13.2%
In Vitro Fertilisation	\$ 143,529,836	5.3%	\$ 116,331,471	3.7%	-\$ 27,198,364	-18.9%
Special Authority Program	\$ 139,208,937	5.1%	\$ 151,656,216	4.8%	\$ 12,447,279	8.9%
Opiate Dependence Treatment Program	\$ 49,404,634	1.8%	\$ 51,560,961	1.6%	\$ 2,156,327	4.4%
Aboriginal Health Services (GST exclusive)	\$ 40,323,041	1.5%	\$ 42,642,523	1.4%	\$ 2,319,483	5.8%
Botulinum Toxin Program (incl. Dysport)	\$ 36,473,730	1.3%	\$ 42,235,114	1.3%	\$ 5,761,384	15.8%
Human Growth Hormones	\$ 29,098,993	1.1%	\$ 25,503,407	0.8%	-\$ 3,595,586	-12.4%
Paraplegic and Quadriplegic Program	\$ 494,319	0.0%	\$ 390,102	0.0%	-\$ 104,217	-21.1%
Continuing Medication Program	\$ 223,453	0.0%	\$ 187,776	0.0%	-\$ 35,677	-16.0%
Total	\$ 2,724,933,327	100.0%	\$ 3,135,750,822	100.0%	\$ 410,817,495	15.1%

Note:

Expenditure figures refer to payments made through the Department of Human Services and directly from the Department of Health Financial Journaling System.

This data reflects the current definitions of Section 100 programs as published on www.pbs.gov.au.

PBS Expenditure and Prescriptions 2016-17

Table 2(a): PBS Section 85 Subsidised Prescriptions, 2015-16 and 2016-17

Section 85 only, including Drs Bag and under co-payment prescriptions

Patient Category	2015-16		2016-17		PBS Prescriptions Change	PBS Prescriptions Change Percentage
	PBS Prescriptions	Percentage	PBS Prescriptions	Percentage		
Concessional Non-Safety Net	143,379,444	70.3%	144,336,986	73.7%	957,542	0.7%
Concessional Safety Net	43,629,150	21.4%	36,045,418	18.4%	-7,583,732	-17.4%
Total Concessional	187,008,594	91.7%	180,382,404	92.1%	-6,626,190	-3.5%
General Non-Safety Net	13,381,157	6.6%	12,334,542	6.3%	-1,046,615	-7.8%
General Safety Net	3,161,615	1.6%	2,699,345	1.4%	-462,270	-14.6%
Total General	16,542,772	8.1%	15,033,887	7.7%	-1,508,885	-9.1%
Doctors Bag	383,018	0.2%	394,352	0.2%	11,334	3.0%
Total (Over Co-payment)	203,934,384	100.0%	195,810,643	100.0%	-8,123,741	-4.0%
Under Co-payment	81,410,187		84,841,518		3,431,331	4.2%

Table 2(b): PBS Section 85 Government Cost, 2015-16 and 2016-17

Section 85 only, including Drs Bag, excluding under co-payment prescriptions

Patient Category	2015-16		2016-17		Government Cost Change	Government Cost Change Percentage
	Government Cost	Percentage	Government Cost	Percentage		
Concessional Non-Safety Net	\$ 4,680,017,502	58.2%	\$ 5,315,606,905	60.9%	\$ 635,589,403	13.6%
Concessional Safety Net	\$ 1,401,731,236	17.4%	\$ 1,204,716,252	13.8%	-\$ 197,014,985	-14.1%
Total Concessional	\$ 6,081,748,739	75.6%	\$ 6,520,323,157	74.7%	\$ 438,574,418	7.2%
General Non-Safety Net	\$ 1,831,928,629	22.8%	\$ 2,088,188,915	23.9%	\$ 256,260,286	14.0%
General Safety Net	\$ 118,167,856	1.5%	\$ 103,984,977	1.2%	-\$ 14,182,879	-12.0%
Total General	\$ 1,950,096,486	24.2%	\$ 2,192,173,892	25.1%	\$ 242,077,406	12.4%
Doctors Bag	\$ 15,678,551	0.2%	\$ 16,718,674	0.2%	\$ 1,040,123	6.6%
Total (Over Co-payment)	\$ 8,047,523,776	100.0%	\$ 8,729,215,723	100.0%	\$ 681,691,947	8.5%

Table 2(c): RPBS and Section 85 Subsidised Prescriptions for DVA patients, 2015-16 and 2016-17

Section 85 and RPBS items for DVA patients, including under co-payment prescriptions

Patient Category	2015-16		2016-17		Subsidised Prescriptions Change	Subsidised Prescriptions Change Percentage
	Subsidised Prescriptions	Percentage	Subsidised Prescriptions	Percentage		
Repatriation Non-Safety Net	7,383,610	72%	6,969,102	75%	-414,508	-5.6%
Repatriation Safety Net	2,929,469	28%	2,352,437	25%	-577,032	-19.7%
Total Repatriation	10,313,079	100%	9,321,539	100%	-991,540	-9.6%

Table 2(d): RPBS and Section 85 Government Cost for DVA patients, 2015-16 and 2016-17

Section 85 and RPBS items for DVA patients, including under co-payment prescriptions

Patient Category	2015-16		2016-17		Government Cost Change	Government Cost Change Percentage
	Government Cost	Percentage	Government Cost	Percentage		
Repatriation Non-Safety Net	\$ 222,887,587	72%	\$ 205,745,155	74%	-\$ 17,142,431	-7.7%
Repatriation Safety Net	\$ 88,532,676	28%	\$ 71,289,599	26%	-\$ 17,243,077	-19.5%
Total Repatriation	\$ 311,420,262	100%	\$ 277,034,754	100%	-\$ 34,385,508	-11.0%

PBS Expenditure and Prescriptions 2016-17

Table 3(a): PBS Subsidised Prescriptions, Government Cost, Patient Contribution and Average Price, 2016-17

Section 85 only, including Drs Bag, excluding under co-payment prescriptions

Patient Category		PBS subsidised prescriptions	Government Cost	Patient contribution***	Total Cost*	Ave. Price**
2016-17	Concessional Non-Safety Net	144,336,986	\$ 5,315,606,905	\$ 880,418,080	\$ 6,196,024,986	\$ 42.93
	Concessional Safety Net	36,045,418	\$ 1,204,716,252	\$ -	\$ 1,204,716,252	\$ 33.42
	Total Concessional	180,382,404	\$ 6,520,323,157	\$ 880,418,080	\$ 7,400,741,237	\$ 41.03
	General Non-Safety Net	12,334,542	\$ 2,088,188,915	\$ 444,029,285	\$ 2,532,218,200	\$ 205.29
	General Safety Net	2,699,345	\$ 103,984,977	\$ 16,448,625	\$ 120,433,602	\$ 44.62
	Total General	15,033,887	\$ 2,192,173,892	\$ 460,477,909	\$ 2,652,651,802	\$ 176.44
	Total (excluding Drs Bag)	195,416,291	\$ 8,712,497,049	\$ 1,340,895,990	\$ 10,053,393,039	\$ 51.45
	Doctors Bag	394,352	\$ 16,718,674	\$ -	\$ 16,718,674	\$ 42.40
Total (including Drs Bag)	195,810,643	\$ 8,729,215,723	\$ 1,340,895,990	\$ 10,070,111,713	\$ 51.43	

*Total Cost includes cost to the patient and cost to the government for PBS Subsidised Prescriptions.

** Average Price is Total Cost divided by PBS Subsidised Prescriptions.

*** The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

Table 3(b): PBS Prescriptions, Government Cost, Patient Contribution and Average Price by Month of Supply, 2015-16 and 2016-17

Section 85 only, excluding Drs Bag

Year	Month	PBS Subsidised Prescriptions	Under Co-Payment Prescriptions	Total Prescriptions	Government Cost	Patient Contribution***	Total Cost*	Ave. Price**
2015	Jul	17,824,315	7,129,983	24,954,298	\$ 606,337,676	\$ 246,382,349	\$ 728,917,983	\$ 40.89
	Aug	17,420,331	7,237,832	24,658,163	\$ 601,993,196	\$ 237,528,016	\$ 714,565,323	\$ 41.02
	Sep	17,571,948	6,793,893	24,365,841	\$ 626,855,981	\$ 222,346,778	\$ 731,366,178	\$ 41.62
	Oct	17,978,140	6,562,091	24,540,231	\$ 638,502,177	\$ 210,632,678	\$ 736,518,664	\$ 40.97
	Nov	18,050,458	6,240,954	24,291,412	\$ 647,559,179	\$ 197,896,670	\$ 738,160,768	\$ 40.89
	Dec	22,093,227	6,389,742	28,482,969	\$ 784,377,687	\$ 204,757,061	\$ 878,813,154	\$ 39.78
2016	Jan	13,340,491	6,236,745	19,577,236	\$ 487,873,238	\$ 222,098,713	\$ 599,761,125	\$ 44.96
	Feb	14,882,970	6,540,324	21,423,294	\$ 541,612,400	\$ 238,559,644	\$ 664,703,921	\$ 44.66
	Mar	16,156,506	6,937,671	23,094,177	\$ 716,603,449	\$ 255,484,398	\$ 849,645,666	\$ 52.59
	Apr	15,688,002	6,961,713	22,649,715	\$ 731,553,904	\$ 244,197,600	\$ 856,610,959	\$ 54.60
	May	16,375,229	7,247,317	23,622,546	\$ 824,826,007	\$ 250,942,857	\$ 952,038,685	\$ 58.14
	Jun	16,169,749	7,131,917	23,301,666	\$ 823,750,331	\$ 240,055,233	\$ 942,884,224	\$ 58.31
Total		203,551,366	81,410,182	284,961,548	\$ 8,031,845,225	\$ 2,770,881,999	\$ 9,393,986,651	\$ 46.15
2016	Jul	16,095,230	7,154,653	23,249,883	\$ 798,214,295	\$ 234,637,294	\$ 910,777,179	\$ 56.59
	Aug	17,195,960	7,593,580	24,789,540	\$ 837,721,376	\$ 241,195,932	\$ 950,075,407	\$ 55.25
	Sep	16,652,249	7,064,087	23,716,336	\$ 791,749,802	\$ 221,555,928	\$ 893,251,103	\$ 53.64
	Oct	16,657,354	6,918,733	23,576,087	\$ 756,264,416	\$ 209,335,682	\$ 850,691,045	\$ 51.07
	Nov	17,331,726	6,789,197	24,120,923	\$ 779,881,395	\$ 204,904,131	\$ 871,802,418	\$ 50.30
	Dec	19,368,403	6,764,406	26,132,809	\$ 828,918,647	\$ 204,482,473	\$ 919,738,359	\$ 47.49
2017	Jan	13,853,791	6,691,870	20,545,661	\$ 608,629,290	\$ 227,389,697	\$ 723,117,583	\$ 52.20
	Feb	14,199,137	6,557,991	20,757,128	\$ 611,010,171	\$ 227,338,631	\$ 727,449,859	\$ 51.23
	Mar	16,293,800	7,410,079	23,703,879	\$ 714,793,002	\$ 258,276,676	\$ 847,837,304	\$ 52.03
	Apr	14,784,114	6,855,958	21,640,072	\$ 608,476,805	\$ 232,481,817	\$ 728,410,523	\$ 49.27
	May	16,797,766	7,629,716	24,427,482	\$ 703,223,620	\$ 256,565,262	\$ 835,035,077	\$ 49.71
	Jun	16,186,761	7,411,206	23,597,967	\$ 673,614,229	\$ 242,684,356	\$ 795,207,180	\$ 49.13
Total		195,416,291	84,841,476	280,257,767	\$ 8,712,497,049	\$ 2,760,847,878	\$ 10,053,393,039	\$ 51.45

*Total Cost includes cost to the patient and cost to the government for PBS Subsidised Prescriptions.

** Average Price is Total Cost divided by PBS Subsidised Prescriptions.

*** The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

PBS Expenditure and Prescriptions 2016-17

Table 4: PBS Subsidised Prescriptions by Pharmacy State, 2016-17
Section 85 only, excluding Drs Bag and under co-payment prescriptions

PBS subsidised prescriptions	NSW	VIC	QLD	SA	WA	TAS	NT	ACT	Australia
Concessional Non-Safety Net	46,977,528	37,021,396	29,104,656	12,351,379	12,663,704	4,189,946	518,660	1,509,717	144,336,986
Concessional Safety Net	12,517,143	9,087,675	7,133,150	3,040,491	2,821,896	1,054,006	55,468	335,589	36,045,418
General Non-Safety Net	4,000,873	2,907,575	2,529,817	833,661	1,405,831	271,617	116,995	268,173	12,334,542
General Safety Net	926,711	662,734	495,289	194,871	289,142	52,061	9,747	68,790	2,699,345
Total	64,422,255	49,679,380	39,262,912	16,420,402	17,180,573	5,567,630	700,870	2,182,269	195,416,291
Government Cost	NSW	VIC	QLD	SA	WA	TAS	NT	ACT	Australia
Concessional Non-Safety Net	\$ 1,734,806,499	\$ 1,393,662,464	\$ 1,097,006,342	\$ 424,129,497	\$ 437,726,088	\$ 149,627,243	\$ 16,134,845	\$ 62,513,928	\$ 5,315,606,905
Concessional Safety Net	\$ 417,572,555	\$ 301,466,096	\$ 240,260,612	\$ 99,785,763	\$ 95,623,122	\$ 36,063,811	\$ 1,645,202	\$ 12,299,091	\$ 1,204,716,252
General Non-Safety Net	\$ 642,768,018	\$ 560,574,868	\$ 408,688,631	\$ 134,853,766	\$ 236,967,320	\$ 44,868,098	\$ 14,945,981	\$ 44,522,233	\$ 2,088,188,915
General Safety Net	\$ 34,831,009	\$ 26,124,230	\$ 18,059,135	\$ 7,449,802	\$ 12,044,077	\$ 2,285,578	\$ 418,045	\$ 2,773,102	\$ 103,984,977
Total	\$ 2,829,978,081	\$ 2,281,827,658	\$ 1,764,014,720	\$ 666,218,827	\$ 782,360,607	\$ 232,844,729	\$ 33,144,073	\$ 122,108,354	\$ 8,712,497,049
Patient contribution***	NSW	VIC	QLD	SA	WA	TAS	NT	ACT	Australia
Concessional Non-Safety Net	\$ 285,138,253	\$ 229,934,060	\$ 175,693,513	\$ 75,561,391	\$ 76,594,987	\$ 25,535,087	\$ 2,666,694	\$ 9,294,097	\$ 880,418,081
Concessional Safety Net	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
General Non-Safety Net	\$ 141,732,616	\$ 110,118,683	\$ 88,506,317	\$ 30,332,030	\$ 50,642,106	\$ 9,579,185	\$ 3,220,269	\$ 9,898,078	\$ 444,029,285
General Safety Net	\$ 5,620,108	\$ 4,093,378	\$ 3,002,473	\$ 1,187,227	\$ 1,754,586	\$ 312,430	\$ 55,780	\$ 422,643	\$ 16,448,625
Total	\$ 432,490,977	\$ 344,146,121	\$ 267,202,303	\$ 107,080,648	\$ 128,991,679	\$ 35,426,702	\$ 5,942,743	\$ 19,614,818	\$ 1,340,895,990
Total Cost*	NSW	VIC	QLD	SA	WA	TAS	NT	ACT	Australia
Concessional Non-Safety Net	\$ 2,019,944,752	\$ 1,623,596,524	\$ 1,272,699,854	\$ 499,690,888	\$ 514,321,075	\$ 175,162,330	\$ 18,801,538	\$ 71,808,024	\$ 6,196,024,986
Concessional Safety Net	\$ 417,572,555	\$ 301,466,096	\$ 240,260,612	\$ 99,785,763	\$ 95,623,122	\$ 36,063,811	\$ 1,645,202	\$ 12,299,091	\$ 1,204,716,252
General Non-Safety Net	\$ 784,500,634	\$ 670,693,550	\$ 497,194,949	\$ 165,185,796	\$ 287,609,426	\$ 54,447,282	\$ 18,166,250	\$ 54,420,311	\$ 2,532,218,200
General Safety Net	\$ 40,451,117	\$ 30,217,608	\$ 21,061,608	\$ 8,637,029	\$ 13,798,662	\$ 2,598,008	\$ 473,825	\$ 3,195,745	\$ 120,433,602
Total	\$ 3,262,469,058	\$ 2,625,973,779	\$ 2,031,217,023	\$ 773,299,475	\$ 911,352,286	\$ 268,271,431	\$ 39,086,816	\$ 141,723,172	\$ 10,053,393,039
Average Price**	NSW	VIC	QLD	SA	WA	TAS	NT	ACT	Australia
Concessional Non-Safety Net	\$ 43.00	\$ 43.86	\$ 43.73	\$ 40.46	\$ 40.61	\$ 41.81	\$ 36.25	\$ 47.56	\$ 42.93
Concessional Safety Net	\$ 33.36	\$ 33.17	\$ 33.68	\$ 32.82	\$ 33.89	\$ 34.22	\$ 29.66	\$ 36.65	\$ 33.42
General Non-Safety Net	\$ 196.08	\$ 230.67	\$ 196.53	\$ 198.15	\$ 204.58	\$ 200.46	\$ 155.27	\$ 202.93	\$ 205.29
General Safety Net	\$ 43.65	\$ 45.60	\$ 42.52	\$ 44.32	\$ 47.72	\$ 49.90	\$ 48.61	\$ 46.46	\$ 44.62
Total	\$ 50.64	\$ 52.86	\$ 51.73	\$ 47.09	\$ 53.05	\$ 48.18	\$ 55.77	\$ 64.94	\$ 51.45
Population Percentage	NSW	VIC	QLD	SA	WA	TAS	NT	ACT	Australia
Population****	7,670,742	5,996,385	4,808,771	1,702,785	2,603,899	517,404	244,031	393,013	23,940,278
PBS Subsidised Scripts per Capita	8.40	8.28	8.16	9.64	6.60	10.76	2.87	5.55	8.16
PBS Subsidised Scripts Govt Cost per Capita	\$ 368.93	\$ 380.53	\$ 366.83	\$ 391.25	\$ 300.46	\$ 450.02	\$ 135.82	\$ 310.70	\$ 363.93
Population Percentage	32.04%	25.05%	20.09%	7.11%	10.88%	2.16%	1.02%	1.64%	100.00%
PBS Subsidised Scripts Percentage	32.97%	25.42%	20.09%	8.40%	8.79%	2.85%	0.36%	1.12%	100.00%
PBS Subsidised Scripts Govt Cost Percentage	32.48%	26.19%	20.25%	7.65%	8.98%	2.67%	0.38%	1.40%	100.00%
Total Cost Percentage	32.45%	26.12%	20.20%	7.69%	9.07%	2.67%	0.39%	1.41%	100.00%

* Total Cost includes cost to the patient and cost to the government for PBS Subsidised Prescriptions.

** Average Price is Total Cost divided by PBS Subsidised Prescriptions.

*** The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

****Population 31 December 2016, Source: ABS Publication 3101.0

PBS Expenditure and Prescriptions 2016-17

Table 5(a): Top 50 PBS Drugs (Generic Name) Sorted by Highest Government Cost, 2016-17

Section 85 only, including Drs Bag, excluding under co-payment prescriptions

Rank	Drug Name	PBS Subsidised Prescriptions	Government Cost	Patient Contribution***	Total Cost*	Ave. Price**
1	LEDIPASVIR + SOFOSBUVIR	33,365	\$ 753,801,363	\$ 566,398	\$ 754,367,761	\$ 22,609.55
2	SOFOBUVIR	34,369	\$ 680,756,969	\$ 505,667	\$ 681,262,636	\$ 19,822.01
3	ADALIMUMAB	202,989	\$ 314,174,121	\$ 5,261,278	\$ 319,435,399	\$ 1,573.66
4	DACLATASVIR	32,248	\$ 255,899,239	\$ 470,434	\$ 256,369,673	\$ 7,949.94
5	AFLIBERCEPT	190,771	\$ 245,355,691	\$ 2,586,162	\$ 247,941,853	\$ 1,299.68
6	RANIBIZUMAB	157,200	\$ 197,370,363	\$ 1,974,214	\$ 199,344,577	\$ 1,268.10
7	PREGABALIN	3,509,499	\$ 154,415,269	\$ 36,641,604	\$ 191,056,873	\$ 54.44
8	FINGOLIMOD	64,643	\$ 146,217,504	\$ 1,666,701	\$ 147,884,204	\$ 2,287.71
9	DENOSUMAB	513,712	\$ 146,118,913	\$ 5,767,653	\$ 151,886,566	\$ 295.66
10	ETANERCEPT	93,984	\$ 142,039,666	\$ 2,098,340	\$ 144,138,005	\$ 1,533.64
11	ESOMEPRAZOLE	6,282,640	\$ 139,976,689	\$ 31,739,585	\$ 171,716,273	\$ 27.33
12	INSULIN GLARGINE	363,510	\$ 139,382,599	\$ 5,098,591	\$ 144,481,190	\$ 397.46
13	FLUTICASONE + SALMETEROL	2,766,903	\$ 132,443,860	\$ 44,746,953	\$ 177,190,813	\$ 64.04
14	RIVAROXABAN	1,463,430	\$ 107,980,701	\$ 19,096,906	\$ 127,077,606	\$ 86.84
15	ROSUVASTATIN	6,434,060	\$ 95,392,547	\$ 33,388,623	\$ 128,781,170	\$ 20.02
16	BUDESONIDE + EFORMOTEROL	1,871,614	\$ 91,555,977	\$ 33,894,373	\$ 125,450,350	\$ 67.03
17	APIXABAN	1,087,395	\$ 91,402,487	\$ 11,966,642	\$ 103,369,129	\$ 95.06
18	TIOTROPIUM	1,652,909	\$ 83,515,047	\$ 13,706,125	\$ 97,221,172	\$ 58.82
19	IMATINIB	25,800	\$ 81,008,907	\$ 510,503	\$ 81,519,410	\$ 3,159.67
20	MESALAZINE	305,502	\$ 75,166,233	\$ 7,984,086	\$ 83,150,320	\$ 272.18
21	USTEKINUMAB	12,808	\$ 72,444,745	\$ 366,118	\$ 72,810,863	\$ 5,684.80
22	ENZALUTAMIDE	18,679	\$ 69,464,920	\$ 194,370	\$ 69,659,289	\$ 3,729.28
23	GOLIMUMAB	47,500	\$ 67,694,604	\$ 1,167,718	\$ 68,862,322	\$ 1,449.73
24	ATORVASTATIN	7,126,125	\$ 64,650,590	\$ 35,977,805	\$ 100,628,394	\$ 14.12
25	OXYCODONE + NALOXONE	1,678,283	\$ 64,356,549	\$ 11,825,857	\$ 76,182,406	\$ 45.39
26	BUPRENORPHINE	1,284,984	\$ 59,562,329	\$ 8,620,986	\$ 68,183,314	\$ 53.06
27	EZETIMIBE	1,126,860	\$ 59,446,234	\$ 15,340,350	\$ 74,786,583	\$ 66.37
28	OXYCODONE	2,358,432	\$ 58,533,856	\$ 13,241,260	\$ 71,775,116	\$ 30.43
29	PALIPERIDONE	185,487	\$ 58,323,897	\$ 1,849,300	\$ 60,173,197	\$ 324.41
30	GOSERELIN	78,517	\$ 56,768,612	\$ 1,411,280	\$ 58,179,892	\$ 740.98
31	GRAZOPREXIL + ELBASVIR	2,582	\$ 55,082,028	\$ 41,282	\$ 55,123,310	\$ 21,349.07
32	INSULIN ASPART	257,235	\$ 54,366,251	\$ 4,627,731	\$ 58,993,982	\$ 229.34
33	ARIPIPRAZOLE	267,647	\$ 53,255,994	\$ 3,226,132	\$ 56,482,126	\$ 211.03
34	EZETIMIBE + SIMVASTATIN	936,991	\$ 51,799,846	\$ 13,010,036	\$ 64,809,882	\$ 69.17
35	TRAMETINIB	5,797	\$ 51,142,462	\$ 113,377	\$ 51,255,839	\$ 8,841.79
36	DABRAFENIB	5,758	\$ 50,319,336	\$ 112,397	\$ 50,431,733	\$ 8,758.55
37	IRON	182,188	\$ 49,834,425	\$ 4,156,865	\$ 53,991,290	\$ 296.35
38	SITAGLIPTIN + METFORMIN	1,131,467	\$ 47,792,359	\$ 18,533,571	\$ 66,325,931	\$ 58.62
39	LEUPRORELIN	38,240	\$ 46,120,132	\$ 436,496	\$ 46,556,628	\$ 1,217.49
40	TOFACITINIB	28,718	\$ 46,061,972	\$ 535,242	\$ 46,597,214	\$ 1,622.58
41	DIMETHYL FUMARATE	25,352	\$ 45,968,771	\$ 662,190	\$ 46,630,960	\$ 1,839.34
42	DASATINIB	9,096	\$ 44,203,331	\$ 223,686	\$ 44,427,017	\$ 4,884.24
43	INSULIN ASPART + INSULIN ASPART PROTAMINE	190,990	\$ 42,993,445	\$ 2,120,712	\$ 45,114,157	\$ 236.21
44	PANTOPRAZOLE	4,612,269	\$ 42,716,152	\$ 22,646,346	\$ 65,362,498	\$ 14.17
45	SALBUTAMOL	2,872,673	\$ 38,965,030	\$ 12,387,775	\$ 51,352,805	\$ 17.88
46	RUXOLITINIB	7,968	\$ 38,810,634	\$ 107,812	\$ 38,918,447	\$ 4,884.34
47	LEVODOPA + CARBIDOPA ANHYDROUS	263,757	\$ 38,273,541	\$ 1,732,882	\$ 40,006,423	\$ 151.68
48	ENOXAPARIN SODIUM	416,756	\$ 38,094,257	\$ 7,936,258	\$ 46,030,515	\$ 110.45
49	ABIRATERONE	10,139	\$ 36,687,494	\$ 100,302	\$ 36,787,796	\$ 3,628.35
50	RISPERIDONE	532,173	\$ 36,278,027	\$ 3,213,987	\$ 39,492,014	\$ 74.21

*Total Cost includes cost to the patient and cost to the government for PBS Subsidised Prescriptions.

** Average Price is Total Cost divided by PBS Subsidised Prescriptions.

*** The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

PBS Expenditure and Prescriptions 2016-17

Table 5(b): Top 50 PBS Drugs (Generic Name) Sorted by Highest Subsidised Prescriptions, 2016-17
 Section 85 only, including Drs Bag, excluding under co-payment prescriptions

Rank	Drug Name	PBS Subsidised Prescriptions	Government Cost	Patient Contribution***	Total Cost*	Ave. Price**
1	ATORVASTATIN	7,126,125	\$ 64,650,590	\$ 35,977,805	\$ 100,628,394	\$ 14.12
2	ROSUVASTATIN	6,434,060	\$ 95,392,547	\$ 33,388,623	\$ 128,781,170	\$ 20.02
3	ESOMEPRAZOLE	6,282,640	\$ 139,976,689	\$ 31,739,585	\$ 171,716,273	\$ 27.33
4	PANTOPRAZOLE	4,612,269	\$ 42,716,152	\$ 22,646,346	\$ 65,362,498	\$ 14.17
5	PERINDOPRIL	3,825,240	\$ 35,457,922	\$ 19,772,952	\$ 55,230,873	\$ 14.44
6	PREGABALIN	3,509,499	\$ 154,415,269	\$ 36,641,604	\$ 191,056,873	\$ 54.44
7	METFORMIN	3,288,233	\$ 32,492,386	\$ 15,363,704	\$ 47,856,090	\$ 14.55
8	SALBUTAMOL	2,872,673	\$ 38,965,030	\$ 12,387,775	\$ 51,352,805	\$ 17.88
9	FLUTICASONONE + SALMETEROL	2,766,903	\$ 132,443,860	\$ 44,746,953	\$ 177,190,813	\$ 64.04
10	IRBESARTAN	2,691,814	\$ 23,022,257	\$ 13,843,294	\$ 36,865,551	\$ 13.70
11	CEPHALEXIN	2,666,321	\$ 19,949,265	\$ 13,908,661	\$ 33,857,927	\$ 12.70
12	ATENOLOL	2,383,364	\$ 17,107,315	\$ 11,884,363	\$ 28,991,678	\$ 12.16
13	OXYCODONE	2,358,432	\$ 58,533,856	\$ 13,241,260	\$ 71,775,116	\$ 30.43
14	AMLODIPINE	2,265,140	\$ 15,585,453	\$ 11,346,670	\$ 26,932,123	\$ 11.89
15	SIMVASTATIN	2,202,371	\$ 17,455,663	\$ 11,006,296	\$ 28,461,959	\$ 12.92
16	AMOXYCILLIN	2,176,321	\$ 16,057,051	\$ 11,860,482	\$ 27,917,533	\$ 12.83
17	AMOXYCILLIN + CLAVULANIC ACID	2,157,393	\$ 18,177,849	\$ 11,213,150	\$ 29,390,999	\$ 13.62
18	PARACETAMOL + CODEINE	2,152,265	\$ 23,690,755	\$ 10,328,472	\$ 34,019,227	\$ 15.81
19	RAMIPRIL	2,106,428	\$ 17,355,047	\$ 10,594,661	\$ 27,949,708	\$ 13.27
20	TELMISARTAN	2,005,133	\$ 21,331,386	\$ 10,638,064	\$ 31,969,450	\$ 15.94
21	CANDESARTAN	1,975,699	\$ 18,702,327	\$ 10,288,836	\$ 28,991,162	\$ 14.67
22	BUDESONIDE + EFOMOTEROL	1,871,614	\$ 91,555,977	\$ 33,894,373	\$ 125,450,350	\$ 67.03
23	SERTRALINE	1,869,817	\$ 14,588,353	\$ 9,842,575	\$ 24,430,928	\$ 13.07
24	TRAMADOL	1,855,120	\$ 22,791,731	\$ 8,554,472	\$ 31,346,204	\$ 16.90
25	RABEPRAZOLE	1,792,056	\$ 18,997,877	\$ 8,922,054	\$ 27,919,932	\$ 15.58
26	CLOPIDOGREL	1,780,189	\$ 19,541,550	\$ 8,214,404	\$ 27,755,954	\$ 15.59
27	IRBESARTAN + HYDROCHLOROTHIAZIDE	1,749,793	\$ 17,692,186	\$ 9,109,761	\$ 26,801,947	\$ 15.32
28	ESCITALOPRAM	1,716,131	\$ 14,168,263	\$ 9,196,375	\$ 23,364,638	\$ 13.61
29	DIAZEPAM	1,693,630	\$ 11,374,394	\$ 8,343,806	\$ 19,718,200	\$ 11.64
30	OXYCODONE + NALOXONE	1,678,283	\$ 64,356,549	\$ 11,825,857	\$ 76,182,406	\$ 45.39
31	MIRTAZAPINE	1,659,431	\$ 17,751,051	\$ 8,111,253	\$ 25,862,303	\$ 15.59
32	TIOTROPIUM	1,652,909	\$ 83,515,047	\$ 13,706,125	\$ 97,221,172	\$ 58.82
33	METOPROLOL TARTRATE	1,642,098	\$ 12,852,172	\$ 7,764,030	\$ 20,616,203	\$ 12.55
34	WARFARIN	1,636,787	\$ 18,701,242	\$ 7,295,414	\$ 25,996,655	\$ 15.88
35	VENLAFAXINE	1,632,854	\$ 19,070,019	\$ 8,695,602	\$ 27,765,621	\$ 17.00
36	LERCANIDIPINE	1,599,354	\$ 14,248,520	\$ 7,852,538	\$ 22,101,058	\$ 13.82
37	OMEPRAZOLE	1,598,711	\$ 18,816,701	\$ 7,884,483	\$ 26,701,184	\$ 16.70
38	RIVAROXABAN	1,463,430	\$ 107,980,701	\$ 19,096,906	\$ 127,077,606	\$ 86.84
39	PARACETAMOL	1,451,627	\$ 18,695,492	\$ 5,786,786	\$ 24,482,278	\$ 16.87
40	AMITRIPTYLINE	1,441,138	\$ 12,843,908	\$ 6,805,900	\$ 19,649,808	\$ 13.63
41	FRUSEMIDE	1,417,002	\$ 11,090,185	\$ 6,056,258	\$ 17,146,443	\$ 12.10
42	TEMAZEPAM	1,414,981	\$ 9,645,018	\$ 6,616,284	\$ 16,261,302	\$ 11.49
43	MELOXICAM	1,404,006	\$ 13,811,047	\$ 7,084,109	\$ 20,895,156	\$ 14.88
44	GLICLAZIDE	1,321,810	\$ 17,168,186	\$ 5,934,620	\$ 23,102,805	\$ 17.48
45	BUPRENORPHINE	1,284,984	\$ 59,562,329	\$ 8,620,986	\$ 68,183,314	\$ 53.06
46	PREDNISOLONE	1,257,064	\$ 10,173,705	\$ 5,971,482	\$ 16,145,186	\$ 12.84
47	PERINDOPRIL + AMLODIPINE	1,220,799	\$ 13,792,806	\$ 6,634,858	\$ 20,427,664	\$ 16.73
48	DESVENLAFAXINE	1,183,808	\$ 34,619,043	\$ 9,984,675	\$ 44,603,718	\$ 37.68
49	MACROGOL-3350 + SODIUM CHLORIDE + BICARBONATE + POTASSIUM CHLORIDE	1,158,768	\$ 17,365,353	\$ 5,073,391	\$ 22,438,744	\$ 19.36
50	SITAGLIPTIN + METFORMIN	1,131,467	\$ 47,792,359	\$ 18,533,571	\$ 66,325,931	\$ 58.62

*Total Cost includes cost to the patient and cost to the government for PBS Subsidised Prescriptions.

** Average Price is Total Cost divided by PBS Subsidised Prescriptions.

*** The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

PBS Expenditure and Prescriptions 2016-17

Table 6(a): Top 50 PBS Items Codes Sorted by Highest Government Cost, 2016-17
Section 85 only, including Drs Bag, excluding under co-payment prescriptions

Rank	Item Code	Drug Name	Form and Strength	PBS Subsidised Prescriptions	Government Cost	Patient Contribution***	Total Cost*	Ave. Price**
1	10628J	LEDIPASVIR + SOFOSBUVIR	Tablet containing 90 mg ledipasvir with 400 mg sofosbuvir	24,244	\$ 547,418,413	\$ 409,030	\$ 547,827,443	\$ 22,596.41
2	10624E	SOFOBUVIR	Tablet 400 mg	19,345	\$ 381,580,567	\$ 278,356	\$ 381,858,923	\$ 19,739.41
3	10657X	SOFOBUVIR	Tablet 400 mg	15,024	\$ 299,176,402	\$ 227,311	\$ 299,403,713	\$ 19,928.36
4	02168D	AFLIBERCEPT	Solution for intravitreal injection 4 mg in 100 microlitres (40 mg per mL)	160,960	\$ 201,555,203	\$ 1,998,265	\$ 203,553,468	\$ 1,264.62
5	10138N	RANIBIZUMAB	Solution for intravitreal injection 1.65 mg in 0.165 mL pre-filled syringe	121,716	\$ 149,852,707	\$ 1,447,980	\$ 151,300,687	\$ 1,243.06
6	05262Y	FINGOLIMOD	Capsule 500 micrograms (as hydrochloride)	64,643	\$ 146,217,504	\$ 1,666,701	\$ 147,884,204	\$ 2,287.71
7	09039R	INSULIN GLARGINE	Injections (human analogue), cartridges, 100 units per mL, 3 mL, 5	363,510	\$ 139,382,599	\$ 5,098,591	\$ 144,481,190	\$ 397.46
8	10670N	LEDIPASVIR + SOFOSBUVIR	Tablet containing 90 mg ledipasvir with 400 mg sofosbuvir	5,876	\$ 133,792,919	\$ 107,818	\$ 133,900,737	\$ 22,787.74
9	10642D	DACLATASVIR	Tablet 60 mg	16,733	\$ 132,239,472	\$ 236,574	\$ 132,476,046	\$ 7,917.05
10	05457F	DENOSUMAB	Injection 60 mg in 1 mL pre-filled syringe	458,548	\$ 119,337,175	\$ 4,901,956	\$ 124,239,132	\$ 270.94
11	10659B	DACLATASVIR	Tablet 60 mg	14,686	\$ 117,098,571	\$ 221,616	\$ 117,320,186	\$ 7,988.57
12	02268J	RIVAROXABAN	Tablet 20 mg	1,060,193	\$ 76,576,500	\$ 15,148,303	\$ 91,724,803	\$ 86.52
13	09100Y	ADALIMUMAB	Injection 40 mg in 0.8 mL pre-filled pen	48,528	\$ 74,334,736	\$ 1,053,321	\$ 75,388,057	\$ 1,553.50
14	08519J	FLUTICASONE + SALMETEROL	Pressurised inhalation containing fluticasone propionate 250 micrograms with salmeterol 25 micrograms (as xinafoate) per dose, 120 doses (CFC-free formulation)	1,356,159	\$ 74,327,206	\$ 20,128,754	\$ 94,455,960	\$ 69.65
15	10668L	LEDIPASVIR + SOFOSBUVIR	Tablet containing 90 mg ledipasvir with 400 mg sofosbuvir	3,245	\$ 72,590,032	\$ 49,550	\$ 72,639,581	\$ 22,385.08
16	10174L	ENZALUTAMIDE	Capsule 40 mg	18,679	\$ 69,464,920	\$ 194,370	\$ 69,659,289	\$ 3,729.28
17	08626B	TIOTROPIUM	Capsule containing powder for oral inhalation 18 micrograms (as bromide monohydrate) (for use in HandiHaler)	1,316,983	\$ 66,860,312	\$ 10,596,874	\$ 77,457,186	\$ 58.81
18	08601Q	ESOMEPRAZOLE	Tablet (enteric coated) 40 mg (as magnesium trihydrate)	2,271,340	\$ 62,348,966	\$ 11,116,092	\$ 73,465,059	\$ 32.34
19	08757X	EZETIMIBE	Tablet 10 mg	1,126,860	\$ 59,446,234	\$ 15,340,350	\$ 74,786,583	\$ 66.37
20	08600P	ESOMEPRAZOLE	Tablet (enteric coated) 20 mg (as magnesium trihydrate)	3,207,021	\$ 58,657,653	\$ 16,325,144	\$ 74,982,798	\$ 23.38
21	02335X	PREGABALIN	Capsule 75 mg	1,546,928	\$ 56,059,472	\$ 18,909,832	\$ 74,969,304	\$ 48.46
22	02735Y	APIXABAN	Tablet 5 mg	676,953	\$ 56,008,408	\$ 8,504,500	\$ 64,512,908	\$ 95.30
23	08435Y	INSULIN ASPART	Injections (human analogue), cartridges, 100 units per mL, 3 mL, 5	244,081	\$ 52,779,656	\$ 4,340,807	\$ 57,120,463	\$ 234.02
24	09305R	USTEKINUMAB	Injection 45 mg in 0.5 mL	8,945	\$ 52,391,595	\$ 263,382	\$ 52,654,977	\$ 5,886.53
25	09460X	ETANERCEPT	Injection 50 mg in 1 mL single use auto-injector, 4	34,012	\$ 51,348,044	\$ 713,088	\$ 52,061,132	\$ 1,530.67
26	02355Y	PREGABALIN	Capsule 150 mg	883,189	\$ 50,457,511	\$ 10,380,123	\$ 60,837,634	\$ 68.88
27	11021C	GRAZOPREVIOR + ELBASVIR	Tablet containing grazoprevir 100 mg with elbasvir 50 mg	2,342	\$ 49,945,841	\$ 36,527	\$ 49,982,368	\$ 21,341.75
28	10104T	IRON	Injection 500 mg (iron) in 10 mL	182,188	\$ 49,834,425	\$ 4,156,865	\$ 53,991,290	\$ 296.35
29	08093Y	GOSERELIN	Subcutaneous implant (long acting) 10.8 mg (as acetate) in pre-filled injection syringe	45,828	\$ 47,625,099	\$ 503,485	\$ 48,128,584	\$ 1,050.20
30	02966D	DIMETHYL FUMARATE	Capsule (modified release) 240 mg	24,565	\$ 45,297,785	\$ 641,513	\$ 45,939,298	\$ 1,870.11
31	10505X	AFLIBERCEPT	Solution for intravitreal injection 4 mg in 100 microlitres (40 mg per mL)	29,811	\$ 43,800,488	\$ 587,897	\$ 44,388,385	\$ 1,488.99
32	09114Q	IMATINIB	Tablet 400 mg (as mesilate)	13,235	\$ 43,562,878	\$ 257,538	\$ 43,820,416	\$ 3,310.95
33	09191R	ADALIMUMAB	Injection 40 mg in 0.8 mL pre-filled pen	28,313	\$ 43,112,282	\$ 820,494	\$ 43,932,776	\$ 1,551.68
34	08609D	INSULIN ASPART + INSULIN ASPART PROTAMINE	Injections (human analogue), cartridges, 30 units-70 units per mL, 3 mL, 5	190,990	\$ 42,993,445	\$ 2,120,712	\$ 45,114,157	\$ 236.21
35	08625Y	BUDESONIDE + EFORMOTEROL	Powder for oral inhalation in breath actuated device containing budesonide 200 micrograms with eformoterol fumarate dihydrate 6 micrograms per dose, 120 doses	1,089,854	\$ 42,466,355	\$ 20,871,654	\$ 63,338,009	\$ 58.12
36	02698B	ABIRATERONE	Tablet containing abiraterone acetate 250 mg	10,139	\$ 36,687,494	\$ 100,302	\$ 36,787,796	\$ 3,628.35
37	09104E	ADALIMUMAB	Injection 40 mg in 0.8 mL pre-filled pen	23,797	\$ 36,259,693	\$ 679,664	\$ 36,939,357	\$ 1,552.27
38	02744K	APIXABAN	Tablet 2.5 mg	392,830	\$ 34,202,408	\$ 3,261,953	\$ 37,464,362	\$ 95.37
39	08008L	PANTOPRAZOLE	Tablet (enteric coated) 40 mg (as sodium sesquihydrate)	3,523,515	\$ 33,093,182	\$ 17,145,056	\$ 50,238,238	\$ 14.26
40	09102C	ADALIMUMAB	Injection 40 mg in 0.8 mL pre-filled pen	21,091	\$ 32,153,945	\$ 573,736	\$ 32,727,681	\$ 1,551.74
41	08288F	SALBUTAMOL	Pressurised inhalation 100 micrograms (as sulfate) per dose, 200 doses (CFC-free formulation)	2,448,356	\$ 31,875,132	\$ 10,822,110	\$ 42,697,242	\$ 17.44
42	10511F	TOFACITINIB	Tablet 5 mg	19,977	\$ 31,774,502	\$ 367,225	\$ 32,141,727	\$ 1,608.94
43	09043Y	ROSUVASTATIN	Tablet 10 mg (as calcium)	2,324,206	\$ 31,705,722	\$ 12,190,030	\$ 43,895,751	\$ 18.89
44	10003L	DABRAFENIB	Capsule 75 mg (as mesilate)	3,527	\$ 31,607,371	\$ 69,891	\$ 31,677,262	\$ 8,981.36
45	08750M	BUDESONIDE + EFORMOTEROL	Powder for oral inhalation in breath actuated device containing budesonide 400 micrograms with eformoterol fumarate dihydrate 12 micrograms per dose, 60 doses, 2	443,107	\$ 31,040,877	\$ 6,908,769	\$ 37,949,646	\$ 85.64
46	02363J	PREGABALIN	Capsule 300 mg	357,306	\$ 30,937,370	\$ 3,999,173	\$ 34,936,543	\$ 97.78
47	10405P	TRAMETINIB	Tablet 2 mg	3,192	\$ 28,625,325	\$ 63,642	\$ 28,688,966	\$ 8,987.77
48	08970D	LEVODOPA + CARBIDOPA ANHYDROUS	Intestinal gel 20 mg-5 mg per mL, 100 mL	2,898	\$ 27,904,980	\$ 27,578	\$ 27,932,558	\$ 9,638.56
49	02691P	RIVAROXABAN	Tablet 15 mg	356,728	\$ 27,819,023	\$ 3,054,305	\$ 30,873,328	\$ 86.55
50	01416M	DASATINIB	Tablet 100 mg	5,747	\$ 27,512,218	\$ 148,356	\$ 27,660,574	\$ 4,813.05

*Total Cost includes cost to the patient and cost to the government for PBS Subsidised Prescriptions.

** Average Price is Total Cost divided by PBS Subsidised Prescriptions.

*** The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

PBS Expenditure and Prescriptions 2016-17

Table 6(b): Top 50 PBS Items Codes Sorted by Highest Subsidised Prescriptions, 2016-17

Section 85 only, including Drs Bag, excluding under co-payment prescriptions

Rank	Item Code	Drug Name	Form and Strength	PBS Subsidised Prescriptions	Government Cost	Patient Contribution***	Total Cost*	Ave. Price**
1	08008L	PANTOPRAZOLE	Tablet (enteric coated) 40 mg (as sodium sesquihydrate)	3,523,515	\$ 33,093,182	\$ 17,145,056	\$ 50,238,238	\$ 14.26
2	08600P	ESOMEPRAZOLE	Tablet (enteric coated) 20 mg (as magnesium trihydrate)	3,207,021	\$ 58,657,653	\$ 16,325,144	\$ 74,982,798	\$ 23.38
3	08215J	ATORVASTATIN	Tablet 40 mg (as calcium)	2,517,635	\$ 24,175,810	\$ 12,573,915	\$ 36,749,725	\$ 14.60
4	08288F	SALBUTAMOL	Pressurised inhalation 100 micrograms (as sulfate) per dose, 200 doses (CFC-free formulation)	2,448,356	\$ 31,875,132	\$ 10,822,110	\$ 42,697,242	\$ 17.44
5	01081X	ATENOLOL	Tablet 50 mg	2,382,712	\$ 17,092,460	\$ 11,880,911	\$ 28,973,371	\$ 12.16
6	09043Y	ROSUVASTATIN	Tablet 10 mg (as calcium)	2,324,206	\$ 31,705,722	\$ 12,190,030	\$ 43,895,751	\$ 18.89
7	08601Q	ESOMEPRAZOLE	Tablet (enteric coated) 40 mg (as magnesium trihydrate)	2,271,340	\$ 62,348,966	\$ 11,116,092	\$ 73,465,059	\$ 32.34
8	03119E	CEPHALEXIN	Capsule 500 mg (anhydrous)	2,196,506	\$ 15,819,267	\$ 11,412,018	\$ 27,231,285	\$ 12.40
9	08214H	ATORVASTATIN	Tablet 20 mg (as calcium)	2,139,710	\$ 17,682,142	\$ 10,997,480	\$ 28,679,622	\$ 13.40
10	08254K	AMOXYCILLIN + CLAVULANIC ACID	Tablet containing 875 mg amoxicillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate)	1,714,742	\$ 14,321,001	\$ 8,798,159	\$ 23,119,160	\$ 13.48
11	08508T	RABEPRAZOLE	Tablet containing rabeprazole sodium 20 mg (enteric coated)	1,581,399	\$ 16,971,049	\$ 7,846,796	\$ 24,817,845	\$ 15.69
12	02335X	PREGABALIN	Capsule 75 mg	1,546,928	\$ 56,059,472	\$ 18,909,832	\$ 74,969,304	\$ 48.46
13	02622B	OXYCODONE	Tablet containing oxycodone hydrochloride 5 mg	1,510,060	\$ 21,279,754	\$ 7,575,674	\$ 28,855,428	\$ 19.11
14	03162K	DIAZEPAM	Tablet 5 mg	1,500,245	\$ 9,932,464	\$ 7,430,136	\$ 17,362,600	\$ 11.57
15	08358X	CLOPIDOGREL	Tablet 75 mg (as hydrogen sulfate)	1,434,190	\$ 15,711,386	\$ 6,647,300	\$ 22,358,686	\$ 15.59
16	02751T	AMLODIPINE	Tablet 5 mg (as besylate)	1,414,350	\$ 9,276,564	\$ 7,156,045	\$ 16,432,609	\$ 11.62
17	02089Y	TEMAZEPAM	Tablet 10 mg	1,395,055	\$ 9,475,015	\$ 6,529,927	\$ 16,004,943	\$ 11.47
18	01324Q	METOPROLOL TARTRATE	Tablet containing metoprolol tartrate 50 mg	1,357,844	\$ 10,459,170	\$ 6,431,736	\$ 16,890,906	\$ 12.44
19	08519J	FLUTICASONE + SALMETEROL	Pressurised inhalation containing fluticasone propionate 250 micrograms with salmeterol 25 micrograms (as xinafoate) per dose, 120 doses (CFC-free formulation)	1,356,159	\$ 74,327,206	\$ 20,128,754	\$ 94,455,960	\$ 69.65
20	01889K	AMOXYCILLIN	Capsule 500 mg (as trihydrate)	1,340,307	\$ 9,369,928	\$ 7,143,536	\$ 16,513,465	\$ 12.32
21	08626B	TIOTROPIUM	Capsule containing powder for oral inhalation 18 micrograms (as bromide monohydrate) (for use in HandiHaler)	1,316,983	\$ 66,860,312	\$ 10,596,874	\$ 77,457,186	\$ 58.81
22	01215Y	PARACETAMOL + CODEINE	Tablet containing codeine phosphate 30 mg with paracetamol 500 mg	1,295,327	\$ 8,867,575	\$ 6,387,258	\$ 15,254,833	\$ 11.78
23	09042X	ROSUVASTATIN	Tablet 5 mg (as calcium)	1,244,913	\$ 13,568,126	\$ 6,601,043	\$ 20,169,169	\$ 16.20
24	08248D	IRBESARTAN	Tablet 300 mg	1,155,602	\$ 11,617,432	\$ 5,857,007	\$ 17,474,439	\$ 15.12
25	08757X	EZETIMIBE	Tablet 10 mg	1,126,860	\$ 59,446,234	\$ 15,340,350	\$ 74,786,583	\$ 66.37
26	08612G	MACROGOL-3350 + SODIUM CHLORIDE + BICARBONATE + POTASSIUM CHLORIDE	Sachets containing powder for oral solution 13.125 g with electrolytes, 30	1,124,939	\$ 16,683,869	\$ 4,927,865	\$ 21,611,734	\$ 19.21
27	08355R	TELMISARTAN	Tablet 40 mg	1,099,798	\$ 8,897,203	\$ 5,896,398	\$ 14,793,602	\$ 13.45
28	08625Y	BUDESONIDE + EFORMOTEROL	Powder for oral inhalation in breath actuated device containing budesonide 200 micrograms with eformoterol fumarate dihydrate 6 micrograms per dose, 120 doses	1,089,854	\$ 42,466,355	\$ 20,871,654	\$ 63,338,009	\$ 58.12
29	08213G	ATORVASTATIN	Tablet 10 mg (as calcium)	1,066,258	\$ 7,716,591	\$ 5,572,463	\$ 13,289,055	\$ 12.46
30	09302N	GLICLAZIDE	Tablet 60 mg (modified release)	1,060,263	\$ 14,003,352	\$ 4,794,425	\$ 18,797,778	\$ 17.73
31	02268J	RIVAROXABAN	Tablet 20 mg	1,060,193	\$ 76,576,500	\$ 15,148,303	\$ 91,724,803	\$ 86.52
32	02412Y	FRUSEMIDE	Tablet 40 mg	1,039,948	\$ 8,122,348	\$ 4,406,390	\$ 12,528,738	\$ 12.05
33	08247C	IRBESARTAN	Tablet 150 mg	1,014,166	\$ 7,737,336	\$ 5,298,012	\$ 13,035,347	\$ 12.85
34	08243W	LATANOPROST	Eye drops 50 micrograms per mL, 2.5 mL	1,003,653	\$ 14,247,750	\$ 4,844,250	\$ 19,092,000	\$ 19.02
35	03439B	METFORMIN	Tablet (extended release) containing metformin hydrochloride 1 g	977,015	\$ 9,993,731	\$ 4,605,372	\$ 14,599,103	\$ 14.94
36	08405J	IRBESARTAN + HYDROCHLOROTHIAZIDE	Tablet 300 mg-12.5 mg	962,851	\$ 10,097,596	\$ 5,004,417	\$ 15,102,013	\$ 15.68
37	08521L	ATORVASTATIN	Tablet 80 mg (as calcium)	938,212	\$ 10,786,025	\$ 4,551,417	\$ 15,337,442	\$ 16.35
38	08173E	SIMVASTATIN	Tablet 40 mg	925,026	\$ 7,659,180	\$ 4,589,254	\$ 12,248,434	\$ 13.24
39	02237R	SERTRALINE	Tablet 100 mg (as hydrochloride)	920,273	\$ 7,505,995	\$ 4,863,923	\$ 12,369,918	\$ 13.44
40	09023X	FENOFIBRATE	Tablet 145 mg	908,994	\$ 22,042,737	\$ 14,132,778	\$ 36,175,515	\$ 39.80
41	08356T	TELMISARTAN	Tablet 80 mg	905,335	\$ 12,434,183	\$ 4,741,666	\$ 17,175,848	\$ 18.97
42	02355Y	PREGABALIN	Capsule 150 mg	883,189	\$ 50,457,511	\$ 10,380,123	\$ 60,837,634	\$ 68.88
43	08302Y	VENLAFAXINE	Capsule (modified release) 150 mg (as hydrochloride)	854,346	\$ 11,080,747	\$ 4,599,602	\$ 15,680,349	\$ 18.35
44	02752W	AMLODIPINE	Tablet 10 mg (as besylate)	850,790	\$ 6,308,889	\$ 4,190,625	\$ 10,499,514	\$ 12.34
45	09110L	OMEPRAZOLE	Tablet 20 mg (as magnesium)	850,344	\$ 10,700,482	\$ 4,214,826	\$ 14,915,308	\$ 17.54
46	08814X	PARACETAMOL	Tablet 665 mg (modified release)	847,801	\$ 11,686,645	\$ 3,454,210	\$ 15,140,855	\$ 17.86
47	09044B	ROSUVASTATIN	Tablet 20 mg (as calcium)	847,699	\$ 14,730,420	\$ 4,340,687	\$ 19,071,108	\$ 22.50
48	03051N	PERINDOPRIL	Tablet containing perindopril erbumine 4 mg	843,103	\$ 7,502,855	\$ 4,409,725	\$ 11,912,581	\$ 14.13
49	08534E	LERCANIDIPINE	Tablet containing lercanidipine hydrochloride 10 mg	830,109	\$ 6,756,965	\$ 4,122,763	\$ 10,879,729	\$ 13.11
50	08701Y	ESCITALOPRAM	Tablet 20 mg (as oxalate)	824,178	\$ 6,921,035	\$ 4,425,006	\$ 11,346,041	\$ 13.77

*Total Cost includes cost to the patient and cost to the government for PBS Subsidised Prescriptions.

** Average Price is Total Cost divided by PBS Subsidised Prescriptions.

*** The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

PBS Expenditure and Prescriptions 2016-17

Table 7: Top 50 ATC Level 2 Drug Groups Sorted by Highest Total Prescription Volume, 2016-17

Section 85 only, including Drs Bag and under co-payment prescriptions

Rank	ATC Level 2 Group	PBS Subsidised Prescriptions	Under Co-Payment Prescriptions	Total Prescriptions
1	AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM	22,402,837	12,605,710	35,008,547
2	LIPID MODIFYING AGENTS	21,094,535	7,677,861	28,772,396
3	ANTIBACTERIALS FOR SYSTEMIC USE	12,389,460	14,281,326	26,670,786
4	PSYCHOANALEPTICS	15,312,751	10,777,991	26,090,742
5	DRUGS FOR ACID RELATED DISORDERS	15,662,944	6,621,224	22,284,168
6	ANALGESICS	16,670,083	4,814,478	21,484,561
7	DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES	11,520,780	1,305,196	12,825,976
8	DRUGS USED IN DIABETES	9,911,233	2,127,389	12,038,622
9	PSYCHOLEPTICS	7,495,120	1,807,517	9,302,637
10	ANTITHROMBOTIC AGENTS	7,968,282	1,002,672	8,970,954
11	CALCIUM CHANNEL BLOCKERS	6,184,456	2,165,279	8,349,735
12	BETA BLOCKING AGENTS	6,054,375	2,002,993	8,057,368
13	OPHTHALMOLOGICALS	6,433,674	1,172,624	7,606,298
14	ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS	3,762,084	3,009,491	6,771,575
15	SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM	2,067,787	3,209,313	5,277,100
16	CORTICOSTEROIDS FOR SYSTEMIC USE	2,249,354	1,824,825	4,074,179
17	CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS	2,159,573	1,421,951	3,581,524
18	CARDIAC THERAPY	2,905,072	444,849	3,349,921
19	DIURETICS	2,277,075	473,413	2,750,488
20	ANTIEPILEPTICS	2,118,012	563,242	2,681,254
21	DRUGS FOR TREATMENT OF BONE DISEASES	1,988,483	178,861	2,167,344
22	ANTIHYPERTENSIVES	1,489,804	443,218	1,933,022
23	THYROID THERAPY	1,041,324	801,813	1,843,137
24	ANTIGOUT PREPARATIONS	1,131,245	690,627	1,821,872
25	DRUGS FOR CONSTIPATION	1,373,038	69,490	1,442,528
26	UROLOGICALS	1,160,630	232,804	1,393,434
27	ANTIEMETICS AND ANTINAUSEANTS	911,692	429,498	1,341,190
28	DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS	876,369	449,043	1,325,412
29	ANTI-PARKINSON DRUGS	1,106,889	121,593	1,228,482
30	IMMUNOSUPPRESSANTS	1,006,657	124,476	1,131,133
31	OTOLOGICALS	579,732	491,682	1,071,414
32	ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS	867,723	65,120	932,843
33	ENDOCRINE THERAPY	688,101	211,699	899,800
34	ANTIVIRALS FOR SYSTEMIC USE	524,763	355,527	880,290
35	ANTI-ANEMIC PREPARATIONS	617,206	101,525	718,731
36	OTHER NERVOUS SYSTEM DRUGS	621,490	2,201	623,691
37	ANTINEOPLASTIC AGENTS	497,565	71,195	568,760
38	ANTI-ACNE PREPARATIONS	219,236	149,540	368,776
39	MINERAL SUPPLEMENTS	285,209	52,062	337,271
40	ANTIPSORIATICS	237,345	31,267	268,612
41	COUGH AND COLD PREPARATIONS	148,488	67,590	216,078
42	MUSCLE RELAXANTS	166,049	45,734	211,783
43	MISSING ITEM CODE	143,058	42,589	185,647
44	OTHER GYNECOLOGICALS	171,227	6,048	177,275
45	STOMATOLOGICAL PREPARATIONS	100,461	45,444	145,905
46	VITAMINS	116,256	28,027	144,283
47	DIGESTIVES, INCL. ENZYMES	140,519	328	140,847
48	ANTIFUNGALS FOR DERMATOLOGICAL USE	77,529	56,831	134,360
49	ANTIMYCOTICS FOR SYSTEMIC USE	86,134	32,713	118,847
50	ALL OTHER THERAPEUTIC PRODUCTS	84,522	2,982	87,504

Table 8: Top 50 Drugs (Generic Name) Sorted by Highest Total Prescription Volume, 2016-17

Section 85 only, including Drs Bag and under co-payment prescriptions

Rank	Drug Name	PBS Subsidised Prescriptions	PBS Non-Subsidised Prescriptions	Total Prescription Volume
1	ATORVASTATIN	7,126,125	2,970,079	10,096,204
2	ROSUVASTATIN	6,434,060	3,608,887	10,042,947
3	ESOMEPRAZOLE	6,282,640	2,732,339	9,014,979
4	PANTOPRAZOLE	4,612,269	1,907,927	6,520,196
5	PERINDOPRIL	3,825,240	2,213,337	6,038,577
6	AMOXYCILLIN	2,176,321	3,237,570	5,413,891
7	CEPHALEXIN	2,666,321	2,696,678	5,362,999
8	METFORMIN	3,288,233	1,571,761	4,859,994
9	AMOXYCILLIN + CLAVULANIC ACID	2,157,393	2,694,550	4,851,943
10	IRBESARTAN	2,691,814	1,269,699	3,961,513
11	SERTRALINE	1,869,817	1,894,415	3,764,232
12	ESCITALOPRAM	1,716,131	2,044,751	3,760,882
13	PREGABALIN	3,509,499	169,965	3,679,464
14	SALBUTAMOL	2,872,673	739,874	3,612,547
15	PARACETAMOL + CODEINE	2,152,265	1,385,426	3,537,691
16	OXYCODONE	2,358,432	1,103,314	3,461,746
17	TELMISARTAN	2,005,133	1,301,585	3,306,718
18	ATENOLOL	2,383,364	894,846	3,278,210
19	AMLODIPINE	2,265,140	944,307	3,209,447
20	RAMIPRIL	2,106,428	1,049,605	3,156,033
21	CANDESARTAN	1,975,699	1,066,130	3,041,829
22	VENLAFAXINE	1,632,854	1,216,521	2,849,375
23	SIMVASTATIN	2,202,371	573,176	2,775,547
24	FLUTICASONE + SALMETEROL	2,766,903	64	2,766,967
25	RABEPRAZOLE	1,792,056	871,367	2,663,423
26	TRAMADOL	1,855,120	772,911	2,628,031
27	IRBESARTAN + HYDROCHLOROTHIAZIDE	1,749,793	812,452	2,562,245
28	DIAZEPAM	1,693,630	711,370	2,405,000
29	MELOXICAM	1,404,006	976,772	2,380,778
30	OMEPRAZOLE	1,598,711	640,316	2,239,027
31	MIRTAZAPINE	1,659,431	569,532	2,228,963
32	PREDNISOLONE	1,257,064	947,489	2,204,553
33	CLOPIDOGREL	1,780,189	367,457	2,147,646
34	METOPROLOL TARTRATE	1,642,098	498,239	2,140,337
35	DESVENLAFAXINE	1,183,808	945,687	2,129,495
36	AMITRIPTYLINE	1,441,138	673,528	2,114,666
37	LERCANIDIPINE	1,599,354	513,821	2,113,175
38	DOXYCYCLINE	1,015,679	1,097,197	2,112,876
39	PERINDOPRIL + AMLODIPINE	1,220,799	878,463	2,099,262
40	LEVONORGESTREL + ETHINYLOESTRADIOL	443,653	1,615,386	2,059,039
41	WARFARIN	1,636,787	419,949	2,056,736
42	OXYCODONE + NALOXONE	1,678,283	306,577	1,984,860
43	TEMAZEPAM	1,414,981	537,154	1,952,135
44	BUDESONIDE + EFORMOTEROL	1,871,614	2,152	1,873,766
45	FLUOXETINE	879,507	892,258	1,771,765
46	GLICLAZIDE	1,321,810	439,697	1,761,507
47	THYROXINE	947,810	755,107	1,702,917
48	CITALOPRAM	940,516	732,107	1,672,623
49	TIOTROPIUM	1,652,909	59	1,652,968
50	CELECOXIB	988,211	639,992	1,628,203

PBS Expenditure and Prescriptions 2016-17

Table 9: Top 50 PBS Item Codes Sorted by Highest Total Prescription Volume, 2016-17

Section 85 only, including Drs Bag and under co-payment prescriptions

Rank	Item Code	Drug Name	Form and Strength	PBS Subsidised Prescriptions	Under Co-Payment Prescriptions	Total Prescription Volume
1	08008L	PANTOPRAZOLE	Tablet (enteric coated) 40 mg (as sodium sesquihydrate)	3,523,515	1,349,429	4,872,944
2	08600P	ESOMEPRAZOLE	Tablet (enteric coated) 20 mg (as magnesium trihydrate)	3,207,021	1,499,374	4,706,395
3	03119E	CEPHALEXIN	Capsule 500 mg (anhydrous)	2,196,506	2,133,059	4,329,565
4	08254K	AMOXYCILLIN + CLAVULANIC ACID	Tablet containing 875 mg amoxicillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate)	1,714,742	2,052,023	3,766,765
5	09043Y	ROSUVASTATIN	Tablet 10 mg (as calcium)	2,324,206	1,343,496	3,667,702
6	08215J	ATORVASTATIN	Tablet 40 mg (as calcium)	2,517,635	993,672	3,511,307
7	01081X	ATENOLOL	Tablet 50 mg	2,382,712	894,277	3,276,989
8	08288F	SALBUTAMOL	Pressurised inhalation 100 micrograms (as sulfate) per dose, 200 doses (CFC-free formulation)	2,448,356	676,060	3,124,416
9	08601Q	ESOMEPRAZOLE	Tablet (enteric coated) 40 mg (as magnesium trihydrate)	2,271,340	839,313	3,110,653
10	01889K	AMOXYCILLIN	Capsule 500 mg (as trihydrate)	1,340,307	1,769,026	3,109,333
11	08214H	ATORVASTATIN	Tablet 20 mg (as calcium)	2,139,710	922,214	3,061,924
12	02622B	OXYCODONE	Tablet containing oxycodone hydrochloride 5 mg	1,510,060	950,751	2,460,811
13	01215Y	PARACETAMOL + CODEINE	Tablet containing codeine phosphate 30 mg with paracetamol 500 mg	1,295,327	1,122,671	2,417,998
14	08508T	RABEPRAZOLE	Tablet containing rabeprazole sodium 20 mg (enteric coated)	1,581,399	754,979	2,336,378
15	03162K	DIAZEPAM	Tablet 5 mg	1,500,245	596,811	2,097,056
16	02751T	AMLODIPINE	Tablet 5 mg (as besylate)	1,414,350	563,879	1,978,229
17	09042X	ROSUVASTATIN	Tablet 5 mg (as calcium)	1,244,913	687,090	1,932,003
18	02089Y	TEMAZEPAM	Tablet 10 mg	1,395,055	534,285	1,929,340
19	08355R	TELMISARTAN	Tablet 40 mg	1,099,798	767,136	1,866,934
20	02237R	SERTRALINE	Tablet 100 mg (as hydrochloride)	920,273	902,783	1,823,056
21	08700X	ESCITALOPRAM	Tablet 10 mg (as oxalate)	796,614	991,298	1,787,912
22	01324Q	METOPROLOL TARTRATE	Tablet containing metoprolol tartrate 50 mg	1,357,844	417,921	1,775,765
23	08701Y	ESCITALOPRAM	Tablet 20 mg (as oxalate)	824,178	926,654	1,750,832
24	08358X	CLOPIDOGREL	Tablet 75 mg (as hydrogen sulfate)	1,434,190	298,581	1,732,771
25	08248D	IRBESARTAN	Tablet 300 mg	1,155,602	507,438	1,663,040
26	01394J	LEVONORGESTREL + ETHINYLOESTRADIOL	Pack containing 21 tablets 150 micrograms-30 micrograms and 7 inert tablets	356,828	1,306,180	1,663,008
27	02236Q	SERTRALINE	Tablet 50 mg (as hydrochloride)	792,854	845,776	1,638,630
28	02335X	PREGABALIN	Capsule 75 mg	1,546,928	4,114	1,551,042
29	08247C	IRBESARTAN	Tablet 150 mg	1,014,166	534,100	1,548,266
30	03439B	METFORMIN	Tablet (extended release) containing metformin hydrochloride 1 g	977,015	564,466	1,541,481
31	08213G	ATORVASTATIN	Tablet 10 mg (as calcium)	1,066,258	460,681	1,526,939
32	03051N	PERINDOPRIL	Tablet containing perindopril erbumine 4 mg	843,103	625,430	1,468,533
33	08356T	TELMISARTAN	Tablet 80 mg	905,335	534,449	1,439,784
34	09302N	GLICLAZIDE	Tablet 60 mg (modified release)	1,060,263	373,210	1,433,473
35	08302Y	VENLAFAXINE	Capsule (modified release) 150 mg (as hydrochloride)	854,346	551,721	1,406,067
36	08405J	IRBESARTAN + HYDROCHLOROTHIAZIDE	Tablet 300 mg-12.5 mg	962,851	439,451	1,402,302
37	09044B	ROSUVASTATIN	Tablet 20 mg (as calcium)	847,699	547,247	1,394,946
38	01434L	FLUOXETINE	Capsule 20 mg (as hydrochloride)	671,715	686,257	1,357,972
39	08519J	FLUTICASONE + SALMETEROL	Pressurised inhalation containing fluticasone propionate 250 micrograms with salmeterol 25 micrograms (as xinafoate) per dose, 120 doses (CFC-free formulation)	1,356,159	2	1,356,161
40	08521L	ATORVASTATIN	Tablet 80 mg (as calcium)	938,212	394,705	1,332,917
41	08626B	TIOTROPIUM	Capsule containing powder for oral inhalation 18 micrograms (as bromide monohydrate) (for use in HandiHaler)	1,316,983	59	1,317,042
42	08220P	CITALOPRAM	Tablet 20 mg (as hydrobromide)	693,601	558,067	1,251,668
43	08440F	CELECOXIB	Capsule 200 mg	760,655	483,438	1,244,093
44	08301X	VENLAFAXINE	Capsule (modified release) 75 mg (as hydrochloride)	673,155	566,752	1,239,907
45	02752W	AMLODIPINE	Tablet 10 mg (as besylate)	850,790	380,428	1,231,218
46	08243W	LATANOPROST	Eye drops 50 micrograms per mL, 2.5 mL	1,003,653	219,423	1,223,076
47	09110L	OMEPRAZOLE	Tablet 20 mg (as magnesium)	850,344	362,676	1,213,020
48	09007C	PERINDOPRIL	Tablet containing perindopril arginine 5 mg	776,265	430,617	1,206,882
49	09156X	DULOXETINE	Capsule 60 mg (as hydrochloride)	711,645	489,469	1,201,114
50	08612G	MACROGOL-3350 + SODIUM CHLORIDE + BICARBONATE + POTASSIUM CHLORIDE	Sachets containing powder for oral solution 13.125 g with electrolytes, 30	1,124,939	56,673	1,181,612

PBS Expenditure and Prescriptions 2016-17

Table 10: ATC Main Groups Comparison for PBS Subsidised Prescriptions, Government Cost, Patient Contribution and Average Price changes, 2015-16 and 2016-17

Section 85 only, including Drs Bag, excluding under co-payment prescriptions

ATC Group Level 1	PBS Subsidised Prescriptions				Government Cost				Patient Contribution***			
	2015-16	2016-17	Prescriptions Change	Percentage Change	2015-16	2016-17	Gov Cost Change	Percentage Change	2015-16	2016-17	Patient Contribution Change	Percentage Change
ALIMENTARY TRACT AND METABOLISM	30,743,410	30,283,673	- 459,737	-1.5%	\$ 979,048,168	\$ 951,046,419	-\$ 28,001,749	-2.9%	\$ 210,252,915	\$ 215,761,405	\$ 5,508,490	2.6%
BLOOD AND BLOOD FORMING ORGANS	9,093,963	8,660,395	- 433,568	-4.8%	\$ 378,012,570	\$ 416,941,385	\$ 38,928,815	10.3%	\$ 71,273,124	\$ 76,181,661	\$ 4,908,537	6.9%
CARDIOVASCULAR SYSTEM	63,864,655	62,409,749	- 1,454,906	-2.3%	\$ 1,050,045,532	\$ 876,840,947	-\$ 173,204,585	-16.5%	\$ 366,451,975	\$ 361,359,164	-\$ 5,092,810	-1.4%
DERMATOLOGICALS	2,896,179	2,781,327	- 114,852	-4.0%	\$ 68,162,140	\$ 62,349,265	-\$ 5,812,875	-8.5%	\$ 27,593,995	\$ 25,602,596	-\$ 1,991,399	-7.2%
GENITO URINARY SYSTEM AND SEX HORMONES	3,290,015	3,399,644	109,629	3.3%	\$ 130,323,010	\$ 132,368,578	\$ 2,045,568	1.6%	\$ 26,049,302	\$ 27,821,289	\$ 1,771,987	6.8%
SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS	3,463,612	3,449,460	- 14,152	-0.4%	\$ 62,877,192	\$ 60,756,295	-\$ 2,120,896	-3.4%	\$ 19,117,210	\$ 19,837,056	\$ 719,846	3.8%
ANTIINFECTIVES FOR SYSTEMIC USE	13,736,742	13,049,363	- 687,379	-5.0%	\$ 1,035,632,471	\$ 1,946,325,020	\$ 910,692,549	87.9%	\$ 86,267,317	\$ 76,499,728	-\$ 9,767,588	-11.3%
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	2,319,031	2,252,168	- 66,863	-2.9%	\$ 1,657,282,566	\$ 1,720,577,414	\$ 63,294,848	3.8%	\$ 41,199,498	\$ 37,209,147	-\$ 3,990,351	-9.7%
MUSCULO-SKELETAL SYSTEM	7,641,026	7,047,861	- 593,165	-7.8%	\$ 270,425,023	\$ 252,561,055	-\$ 17,863,968	-6.6%	\$ 45,979,361	\$ 40,632,599	-\$ 5,346,762	-11.6%
NERVOUS SYSTEM	46,701,649	43,338,482	- 3,363,167	-7.2%	\$ 1,323,195,423	\$ 1,238,716,096	-\$ 84,479,327	-6.4%	\$ 295,691,934	\$ 285,302,358	-\$ 10,389,576	-3.5%
ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS	91,544	85,177	- 6,367	-7.0%	\$ 2,323,142	\$ 2,296,504	-\$ 26,638	-1.1%	\$ 544,087	\$ 662,608	\$ 118,521	21.8%
RESPIRATORY SYSTEM	11,627,111	11,693,468	66,357	0.6%	\$ 450,501,735	\$ 452,135,746	\$ 1,634,010	0.4%	\$ 122,298,834	\$ 129,359,037	\$ 7,060,203	5.8%
SENSORY ORGANS	7,737,991	7,044,196	- 693,795	-9.0%	\$ 566,184,976	\$ 560,388,449	-\$ 5,796,527	-1.0%	\$ 43,124,729	\$ 40,743,662	-\$ 2,381,067	-5.5%
VARIOUS	571,103	172,622	- 398,481	-69.8%	\$ 69,535,556	\$ 51,623,724	-\$ 17,911,833	-25.8%	\$ 5,343,051	\$ 2,991,366	-\$ 2,351,686	-44.0%
UNLESS OTHERWISE CLASSIFIED	156,353	143,058	- 13,295	-8.5%	\$ 3,974,273	\$ 4,288,828	\$ 314,555	7.9%	\$ 954,094	\$ 932,314	-\$ 21,780	-2.3%
TOTAL	203,934,384	195,810,643	- 8,123,741	-4.0%	\$ 8,047,523,776	\$ 8,729,215,723	\$ 681,691,947	8.5%	\$ 1,362,141,426	\$ 1,340,895,990	-\$ 21,245,436	-1.6%

ATC Group Level 1	Total Cost **				Average Price *			
	2015-16	2016-17	Total Cost Change	Percentage Change	2015-16	2016-17	Ave Price Change	Percentage Change
ALIMENTARY TRACT AND METABOLISM	\$ 1,189,301,083	\$ 1,166,807,823	-\$ 22,493,260	-1.9%	\$ 38.68	\$ 38.53	-\$ 0.16	-0.4%
BLOOD AND BLOOD FORMING ORGANS	\$ 449,285,693	\$ 493,123,045	\$ 43,837,352	9.8%	\$ 49.40	\$ 56.94	\$ 7.54	15.3%
CARDIOVASCULAR SYSTEM	\$ 1,416,497,507	\$ 1,238,200,111	-\$ 178,297,396	-12.6%	\$ 22.18	\$ 19.84	-\$ 2.34	-10.5%
DERMATOLOGICALS	\$ 95,756,135	\$ 87,951,861	-\$ 7,804,274	-8.2%	\$ 33.06	\$ 31.62	-\$ 1.44	-4.4%
GENITO URINARY SYSTEM AND SEX HORMONES	\$ 156,372,312	\$ 160,189,867	\$ 3,817,555	2.4%	\$ 47.53	\$ 47.12	-\$ 0.41	-0.9%
SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS	\$ 81,994,402	\$ 80,593,351	-\$ 1,401,051	-1.7%	\$ 23.67	\$ 23.36	-\$ 0.31	-1.3%
ANTIINFECTIVES FOR SYSTEMIC USE	\$ 1,121,899,787	\$ 2,022,824,748	\$ 900,924,961	80.3%	\$ 81.67	\$ 155.01	\$ 73.34	89.8%
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	\$ 1,698,482,064	\$ 1,757,786,561	\$ 59,304,497	3.5%	\$ 732.41	\$ 780.49	\$ 48.08	6.6%
MUSCULO-SKELETAL SYSTEM	\$ 316,404,384	\$ 293,193,654	-\$ 23,210,730	-7.3%	\$ 41.41	\$ 41.60	\$ 0.19	0.5%
NERVOUS SYSTEM	\$ 1,618,887,357	\$ 1,524,018,454	-\$ 94,868,903	-5.9%	\$ 34.66	\$ 35.17	\$ 0.50	1.4%
ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS	\$ 2,867,228	\$ 2,959,112	\$ 91,883	3.2%	\$ 31.32	\$ 34.74	\$ 3.42	10.9%
RESPIRATORY SYSTEM	\$ 572,800,570	\$ 581,494,783	\$ 8,694,213	1.5%	\$ 49.26	\$ 49.73	\$ 0.46	0.9%
SENSORY ORGANS	\$ 609,309,705	\$ 601,132,111	-\$ 8,177,594	-1.3%	\$ 78.74	\$ 85.34	\$ 6.59	8.4%
VARIOUS	\$ 74,878,607	\$ 54,615,089	-\$ 20,263,518	-27.1%	\$ 131.11	\$ 316.39	\$ 185.27	141.3%
UNLESS OTHERWISE CLASSIFIED	\$ 4,928,367	\$ 5,221,142	\$ 292,775	5.9%	\$ 31.52	\$ 36.50	\$ 4.98	15.8%
TOTAL	\$ 9,409,665,202	\$ 10,070,111,713	\$ 660,446,511	7.0%	\$ 46.14	\$ 51.43	\$ 5.29	11.5%

*Total Cost includes cost to the patient and cost to the government for PBS Subsidised Prescriptions.

** Average Price is Total Cost divided by PBS Subsidised Prescriptions.

*** The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

PBS Expenditure and Prescriptions 2016-17

Table 11(a): Top 35 Drugs Sorted by Highest Change to Government Cost, 2015-16 and 2016-17 Section 85 only, including Drs Bag, excluding under co-payment prescriptions

Rank	Drug Name	2015-16					2016-17					Government Cost Change	Government Cost Change Percentage
		PBS Subsidised Prescriptions	Government Cost	Patient Contribution***	Total Cost*	Ave. Price**	PBS Subsidised Prescriptions	Government Cost	Patient Contribution***	Total Cost*	Ave. Price**		
1	SOFOSBUVIR	13,909	\$ 279,247,039	\$ 245,972	\$ 279,493,011	\$ 20,094	34,369	\$ 680,756,969	\$ 505,667	\$ 681,262,636	\$ 19,822	\$ 401,509,930	143.78%
2	LEDIPASVIR + SOFOSBUVIR	19,802	\$ 451,928,429	\$ 404,649	\$ 452,333,079	\$ 22,843	33,365	\$ 753,801,363	\$ 566,398	\$ 754,367,761	\$ 22,610	\$ 301,872,934	66.80%
3	DACLATASVIR	12,900	\$ 103,569,074	\$ 227,373	\$ 103,796,448	\$ 8,046	32,248	\$ 255,899,239	\$ 470,434	\$ 256,369,673	\$ 7,950	\$ 152,330,165	147.08%
4	AFLIBERCEPT	142,042	\$ 211,097,090	\$ 1,749,872	\$ 212,846,963	\$ 1,498	190,771	\$ 245,355,691	\$ 2,586,162	\$ 247,941,853	\$ 1,300	\$ 34,258,601	16.23%
5	APIXABAN	693,320	\$ 59,279,783	\$ 7,370,218	\$ 66,650,000	\$ 96	1,087,395	\$ 91,402,487	\$ 11,966,642	\$ 103,369,129	\$ 95	\$ 32,122,704	54.19%
6	TOFACITINIB	10,269	\$ 17,904,388	\$ 197,832	\$ 18,102,220	\$ 1,763	28,718	\$ 46,061,972	\$ 535,242	\$ 46,597,214	\$ 1,623	\$ 28,157,584	157.27%
7	RUXOLITINIB	2,491	\$ 11,958,971	\$ 35,696	\$ 11,994,667	\$ 4,815	7,968	\$ 38,810,634	\$ 107,812	\$ 38,918,447	\$ 4,884	\$ 26,851,663	224.53%
8	DENOSUMAB	402,790	\$ 121,353,735	\$ 4,401,290	\$ 125,755,025	\$ 312	513,712	\$ 146,118,913	\$ 5,767,653	\$ 151,886,566	\$ 296	\$ 24,765,177	20.41%
9	SECUKINUMAB	7,048	\$ 12,158,810	\$ 204,573	\$ 12,363,383	\$ 1,754	20,026	\$ 35,863,239	\$ 563,783	\$ 36,427,021	\$ 1,819	\$ 23,704,429	194.96%
10	PREGABALIN	3,123,938	\$ 137,746,728	\$ 32,065,722	\$ 169,812,451	\$ 54	3,509,499	\$ 154,415,269	\$ 36,641,604	\$ 191,056,873	\$ 54	\$ 16,668,541	12.10%
11	ENZALUTAMIDE	14,536	\$ 54,085,084	\$ 145,031	\$ 54,230,115	\$ 3,731	18,679	\$ 69,464,920	\$ 194,370	\$ 69,659,289	\$ 3,729	\$ 15,379,836	28.44%
12	IRON	126,106	\$ 34,464,257	\$ 2,774,105	\$ 37,238,362	\$ 295	182,188	\$ 49,834,425	\$ 4,156,865	\$ 53,991,290	\$ 296	\$ 15,370,168	44.60%
13	RIVAROXABAN	1,238,439	\$ 95,214,091	\$ 15,758,014	\$ 110,972,104	\$ 90	1,463,430	\$ 107,980,701	\$ 19,096,906	\$ 127,077,606	\$ 87	\$ 12,766,610	13.41%
14	EZETIMIBE + ATORVASTATIN	190,011	\$ 10,759,627	\$ 3,192,514	\$ 13,952,141	\$ 73	427,572	\$ 22,917,818	\$ 7,168,724	\$ 30,086,542	\$ 70	\$ 12,158,191	113.00%
15	USTEKINUMAB	9,944	\$ 60,345,755	\$ 285,889	\$ 60,631,644	\$ 6,097	12,808	\$ 72,444,745	\$ 366,118	\$ 72,810,863	\$ 5,685	\$ 12,098,990	20.05%
16	EXENATIDE	221,997	\$ 15,749,609	\$ 3,376,579	\$ 19,126,188	\$ 86	313,867	\$ 25,614,865	\$ 4,810,363	\$ 30,425,228	\$ 97	\$ 9,865,256	62.64%
17	TRAMETINIB	4,695	\$ 41,479,983	\$ 93,913	\$ 41,573,896	\$ 8,855	5,797	\$ 51,142,462	\$ 113,377	\$ 51,255,839	\$ 8,842	\$ 9,662,479	23.29%
18	TRASTUZUMAB	93	\$ 278,629	\$ 2,278	\$ 280,907	\$ 3,021	3,233	\$ 9,699,002	\$ 81,733	\$ 9,780,735	\$ 3,025	\$ 9,420,373	3,380.97%
19	LEVODOPA + CARBIDOPA ANHYDROUS	271,862	\$ 29,916,827	\$ 2,029,148	\$ 31,945,975	\$ 118	263,757	\$ 38,273,541	\$ 1,732,882	\$ 40,006,423	\$ 152	\$ 8,356,714	27.93%
20	ROSUVASTATIN (&) EZETIMIBE	198,380	\$ 11,217,513	\$ 3,706,332	\$ 14,923,845	\$ 75	374,444	\$ 19,420,284	\$ 7,108,660	\$ 26,528,944	\$ 71	\$ 8,202,772	73.12%
21	LISDEXAMFETAMINE	62,618	\$ 6,072,381	\$ 1,225,300	\$ 7,297,680	\$ 117	144,187	\$ 13,974,121	\$ 2,853,328	\$ 16,827,450	\$ 117	\$ 7,901,741	130.13%
22	EMPAGLIFLOZIN	65,422	\$ 2,872,618	\$ 1,111,236	\$ 3,983,854	\$ 61	234,235	\$ 10,446,872	\$ 3,852,007	\$ 14,298,878	\$ 61	\$ 7,574,254	263.67%
23	POSACONAZOLE	6,348	\$ 18,219,985	\$ 100,524	\$ 18,320,509	\$ 2,886	8,389	\$ 25,450,626	\$ 133,732	\$ 25,584,358	\$ 3,050	\$ 7,230,641	39.69%
24	TERIFLUNOMIDE	10,887	\$ 19,665,817	\$ 241,104	\$ 19,906,921	\$ 1,829	14,488	\$ 26,279,755	\$ 331,103	\$ 26,610,858	\$ 1,837	\$ 6,613,937	33.63%
25	AXITINIB	493	\$ 2,350,363	\$ 8,928	\$ 2,359,291	\$ 4,786	1,863	\$ 8,759,946	\$ 31,154	\$ 8,791,100	\$ 4,719	\$ 6,409,583	272.71%
26	TIOTROPIUM + OLODATEROL	9,985	\$ 798,743	\$ 98,533	\$ 897,277	\$ 90	85,840	\$ 6,898,682	\$ 782,046	\$ 7,680,728	\$ 89	\$ 6,099,938	763.69%
27	PARITAPREVIR + RITONAVIR + OMBITASVIR + DASABUVIR	122	\$ 1,774,820	\$ 2,722	\$ 1,777,542	\$ 14,570	533	\$ 7,549,437	\$ 10,361	\$ 7,559,798	\$ 14,183	\$ 5,774,617	325.36%
28	FLUTICASONE + VILANTEROL	205,046	\$ 10,051,136	\$ 3,068,416	\$ 13,119,552	\$ 64	323,171	\$ 15,772,594	\$ 5,053,575	\$ 20,826,170	\$ 64	\$ 5,721,458	56.92%
29	DAPAGLIFLOZIN + METFORMIN	31,520	\$ 1,283,028	\$ 618,825	\$ 1,901,853	\$ 60	158,465	\$ 6,478,405	\$ 3,068,212	\$ 9,546,616	\$ 60	\$ 5,195,377	404.93%
30	LURASIDONE	15,673	\$ 1,466,344	\$ 223,093	\$ 1,689,437	\$ 108	62,396	\$ 6,430,674	\$ 891,843	\$ 7,322,517	\$ 117	\$ 4,964,330	338.55%
31	EMPAGLIFLOZIN + METFORMIN	5,496	\$ 245,972	\$ 105,770	\$ 351,742	\$ 64	115,409	\$ 5,180,325	\$ 2,193,369	\$ 7,373,694	\$ 64	\$ 4,934,353	2,006.07%
32	TAPENTADOL	272,492	\$ 9,215,903	\$ 2,362,767	\$ 11,578,670	\$ 42	415,515	\$ 14,047,216	\$ 3,632,516	\$ 17,679,731	\$ 43	\$ 4,831,313	52.42%
33	OXYCODONE + NALOXONE	1,528,023	\$ 59,732,703	\$ 10,503,215	\$ 70,235,917	\$ 46	1,678,283	\$ 64,356,549	\$ 11,825,857	\$ 76,182,406	\$ 45	\$ 4,623,846	7.74%
34	DUTASTERIDE + TAMBUSLOSIN	548,519	\$ 16,683,580	\$ 2,587,320	\$ 19,270,900	\$ 35	711,779	\$ 21,055,565	\$ 3,513,158	\$ 24,568,723	\$ 35	\$ 4,371,986	26.21%
35	SITAGLIPTIN + METFORMIN	977,581	\$ 43,539,436	\$ 15,554,361	\$ 59,093,797	\$ 60	1,131,467	\$ 47,792,359	\$ 18,533,571	\$ 66,325,931	\$ 59	\$ 4,252,923	9.77%

*Total Cost includes cost to the patient and cost to the government for PBS Subsidised Prescriptions.

** Average Price is Total Cost divided by PBS Subsidised Prescriptions.

*** The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

PBS Expenditure and Prescriptions 2016-17

Table 11(b): Top 35 Drugs Sorted by Highest Change to Script Volume, 2015-16 and 2016-17

Section 85 only, including Drs Bag, excluding under co-payment prescriptions

Rank	Drug Name	2015-16					2016-17					Prescription Volume Change	Prescription Volume Change Percentage
		PBS Subsidised Prescriptions	Government Cost	Patient Contribution***	Total Cost*	Ave. Price**	PBS Subsidised Prescriptions	Government Cost	Patient Contribution***	Total Cost*	Ave. Price**		
1	APIXABAN	693,320	\$ 59,279,783	\$ 7,370,218	\$ 66,650,000	\$ 96.13	1,087,395	\$ 91,402,487	\$ 11,966,642	\$ 103,369,129	\$ 95.06	394,075	56.84%
2	PREGABALIN	3,123,938	\$ 137,746,728	\$ 32,065,722	\$ 169,812,451	\$ 54.36	3,509,499	\$ 154,415,269	\$ 36,641,604	\$ 191,056,873	\$ 54.44	385,561	12.34%
3	EZETIMIBE + ATORVASTATIN	190,011	\$ 10,759,627	\$ 3,192,514	\$ 13,952,141	\$ 73.43	427,572	\$ 22,917,818	\$ 7,168,724	\$ 30,086,542	\$ 70.37	237,561	125.02%
4	RIVAROXABAN	1,238,439	\$ 95,214,091	\$ 15,758,014	\$ 110,972,104	\$ 89.61	1,463,430	\$ 107,980,701	\$ 19,096,906	\$ 127,077,606	\$ 86.84	224,991	18.17%
5	ROSUVASTATIN (&) EZETIMIBE	198,380	\$ 11,217,513	\$ 3,706,332	\$ 14,923,845	\$ 75.23	374,444	\$ 19,420,284	\$ 7,108,660	\$ 26,528,944	\$ 70.85	176,064	88.75%
6	EMPAGLIFLOZIN	65,422	\$ 2,872,618	\$ 1,111,236	\$ 3,983,854	\$ 60.89	234,235	\$ 10,446,872	\$ 3,852,007	\$ 14,298,878	\$ 61.05	168,813	258.04%
7	DUTASTERIDE + TAMSULOSIN	548,519	\$ 16,683,580	\$ 2,587,320	\$ 19,270,900	\$ 35.13	711,779	\$ 21,055,565	\$ 3,513,158	\$ 24,568,723	\$ 34.52	163,260	29.76%
8	SITAGLIPTIN + METFORMIN	977,581	\$ 43,539,436	\$ 15,554,361	\$ 59,093,797	\$ 60.45	1,131,467	\$ 47,792,359	\$ 18,533,571	\$ 66,325,931	\$ 58.62	153,886	15.74%
9	OXYCODONE + NALOXONE	1,528,023	\$ 59,732,703	\$ 10,503,215	\$ 70,235,917	\$ 45.97	1,678,283	\$ 64,356,549	\$ 11,825,857	\$ 76,182,406	\$ 45.39	150,260	9.83%
10	TAPENTADOL	272,492	\$ 9,215,903	\$ 2,362,767	\$ 11,578,670	\$ 42.49	415,515	\$ 14,047,216	\$ 3,632,516	\$ 17,679,731	\$ 42.55	143,023	52.49%
11	DAPAGLIFLOZIN + METFORMIN	31,520	\$ 1,283,028	\$ 618,825	\$ 1,901,853	\$ 60.34	158,465	\$ 6,478,405	\$ 3,068,212	\$ 9,546,616	\$ 60.24	126,945	402.74%
12	FLUTICASON + VILANTEROL	205,046	\$ 10,051,136	\$ 3,068,416	\$ 13,119,552	\$ 63.98	323,171	\$ 15,772,594	\$ 5,053,575	\$ 20,826,170	\$ 64.44	118,125	57.61%
13	DENOSUMAB	402,790	\$ 121,353,735	\$ 4,401,290	\$ 125,755,025	\$ 312.21	513,712	\$ 146,118,913	\$ 5,767,653	\$ 151,886,566	\$ 295.66	110,922	27.54%
14	EMPAGLIFLOZIN + METFORMIN	5,496	\$ 245,972	\$ 105,770	\$ 351,742	\$ 64.00	115,409	\$ 5,180,325	\$ 2,193,369	\$ 7,373,694	\$ 63.89	109,913	1,999.87%
15	ROSUVASTATIN	6,336,041	\$ 132,226,484	\$ 33,916,521	\$ 166,143,005	\$ 26.22	6,434,060	\$ 95,392,547	\$ 33,388,623	\$ 128,781,170	\$ 20.02	98,019	1.55%
16	PANTOPRAZOLE	4,515,710	\$ 46,010,464	\$ 21,172,254	\$ 67,182,719	\$ 14.88	4,612,269	\$ 42,716,152	\$ 22,646,346	\$ 65,362,498	\$ 14.17	96,559	2.14%
17	EXENATIDE	221,997	\$ 15,749,609	\$ 3,376,579	\$ 19,126,188	\$ 86.16	313,867	\$ 25,614,865	\$ 4,810,363	\$ 30,425,228	\$ 96.94	91,870	41.38%
18	LISDEXAMFETAMINE	62,618	\$ 6,072,381	\$ 1,225,300	\$ 7,297,680	\$ 116.54	144,187	\$ 13,974,121	\$ 2,853,328	\$ 16,827,450	\$ 116.71	81,569	130.26%
19	DAPAGLIFLOZIN	431,108	\$ 17,640,208	\$ 7,165,326	\$ 24,805,533	\$ 57.54	511,474	\$ 21,067,365	\$ 8,433,952	\$ 29,501,317	\$ 57.68	80,366	18.64%
20	MIRTAZAPINE	1,583,458	\$ 18,796,993	\$ 7,420,493	\$ 26,217,486	\$ 16.56	1,659,431	\$ 17,751,051	\$ 8,111,253	\$ 25,862,303	\$ 15.59	75,973	4.80%
21	TIOTROPIUM + OLODATEROL	9,985	\$ 798,743	\$ 98,533	\$ 897,277	\$ 89.86	85,840	\$ 6,898,682	\$ 782,046	\$ 7,680,728	\$ 89.48	75,855	759.69%
22	BUDESONIDE + EFORMOTEROL	1,795,897	\$ 89,143,381	\$ 31,093,132	\$ 120,236,512	\$ 66.95	1,871,614	\$ 91,555,977	\$ 33,894,373	\$ 125,450,350	\$ 67.03	75,717	4.22%
23	BISOPROLOL	861,222	\$ 19,318,752	\$ 4,043,672	\$ 23,362,425	\$ 27.13	933,554	\$ 16,335,469	\$ 4,478,789	\$ 20,814,258	\$ 22.30	72,332	8.40%
24	OLMESARTAN MEDOXOMIL	590,927	\$ 10,176,126	\$ 3,128,011	\$ 13,304,137	\$ 22.51	649,931	\$ 11,094,925	\$ 3,563,783	\$ 14,658,708	\$ 22.55	59,004	9.98%
25	BRINZOLAMIDE + BRIMONIDINE	15,386	\$ 328,246	\$ 85,982	\$ 414,228	\$ 26.92	73,276	\$ 1,635,493	\$ 350,245	\$ 1,985,738	\$ 27.10	57,890	376.25%
26	IRON	126,106	\$ 34,464,257	\$ 2,774,105	\$ 37,238,362	\$ 295.29	182,188	\$ 49,834,425	\$ 4,156,865	\$ 53,991,290	\$ 296.35	56,082	44.47%
27	DABIGATRAN	308,939	\$ 24,918,046	\$ 3,074,233	\$ 27,992,279	\$ 90.61	360,177	\$ 27,778,659	\$ 3,819,299	\$ 31,597,958	\$ 87.73	51,238	16.59%
28	DOXYCYCLINE	966,441	\$ 7,039,914	\$ 4,661,869	\$ 11,701,782	\$ 12.11	1,015,679	\$ 7,700,996	\$ 5,056,306	\$ 12,757,302	\$ 12.56	49,238	5.09%
29	AFLIBERCEPT	142,042	\$ 211,097,090	\$ 1,749,872	\$ 212,846,963	\$ 1,498.48	190,771	\$ 245,355,691	\$ 2,586,162	\$ 247,941,853	\$ 1,299.68	48,729	34.31%
30	LURASIDONE	15,673	\$ 1,466,344	\$ 223,093	\$ 1,689,437	\$ 107.79	62,396	\$ 6,430,674	\$ 891,843	\$ 7,322,517	\$ 117.36	46,723	298.11%
31	LINAGLIPTIN + METFORMIN	117,265	\$ 5,779,297	\$ 1,783,809	\$ 7,563,106	\$ 64.50	161,821	\$ 7,823,339	\$ 2,480,201	\$ 10,303,540	\$ 63.67	44,556	38.00%
32	OLMESARTAN + AMLODIPINE + HYDROCHLOROTHIAZIDE	118,880	\$ 2,983,543	\$ 616,880	\$ 3,600,423	\$ 30.29	160,330	\$ 3,960,753	\$ 861,871	\$ 4,822,624	\$ 30.08	41,450	34.87%
33	FENOFIBRATE	1,024,096	\$ 26,477,699	\$ 14,407,564	\$ 40,885,263	\$ 39.92	1,065,434	\$ 25,994,931	\$ 15,436,024	\$ 41,430,954	\$ 38.89	41,338	4.04%
34	NEBIVOLOL	214,287	\$ 10,727,931	\$ 1,967,941	\$ 12,695,872	\$ 59.25	254,106	\$ 12,145,625	\$ 2,516,374	\$ 14,661,999	\$ 57.70	39,819	18.58%
35	TELMISARTAN + AMLODIPINE	521,745	\$ 9,638,170	\$ 2,764,780	\$ 12,402,950	\$ 23.77	561,204	\$ 7,129,062	\$ 3,076,669	\$ 10,205,731	\$ 18.19	39,459	7.56%

*Total Cost includes cost to the patient and cost to the government for PBS Subsidised Prescriptions.

** Average Price is Total Cost divided by PBS Subsidised Prescriptions.

*** The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

Table 12(a): PBS Prescription Volume, 2013-14 to 2016-17

Section 85 only, including Drs Bag and under co-payment prescriptions

Prescription Type	2013-14	2014-15	2015-16	2016-17
Over Co-payment	203,061,113	204,429,685	203,934,384	195,810,643
Under Co-payment	70,337,935	76,738,912	81,410,187	84,841,518
Total	273,399,048	281,168,597	285,344,571	280,652,161





Table 12(b): PBS expenditure, 2013-14 to 2016-17

Section 85 only, including Drs Bag, excluding under co-payment prescriptions

Expenditure Type	2013-14	2014-15	2015-16	2016-17
Government Cost	\$ 7,069,175,633	\$ 6,851,505,026	\$ 8,047,523,776	\$ 8,729,215,723
Patient Contribution***	\$ 1,458,891,919	\$ 1,404,249,150	\$ 1,362,141,426	\$ 1,340,895,990
Total Cost*	\$ 8,528,067,552	\$ 8,255,754,176	\$ 9,409,665,202	\$ 10,070,111,713



* Total Cost includes cost to the patient and cost to the government for PBS Subsidised Prescriptions.

*** The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

Table 13: PBS Subsidised Prescriptions and Government Cost by Formulary, 2016-17

Section 85 and Section 100*, excluding Drs Bag and under co-payment prescriptions

Formulary Group ¹	PBS Subsidised Prescriptions	Percentage	Government Cost	Percentage
F1	31,420,457	15.9%	\$ 7,073,273,777	60.2%
F2	152,525,771	77.0%	\$ 2,841,449,589	24.2%
Combination Drugs ²	13,880,272	7.0%	\$ 1,837,269,703	15.6%
Other ³	150,604	0.1%	\$ 4,440,173	0.0%
Total	197,977,104	100.0%	\$ 11,756,433,243	100.0%

Notes:

1. The National Health Act 1953 provides that listed drugs be assigned to formularies identified as F1 or F2. Generally F1 is intended for single brand drugs and F2 for drugs that have multiple brands, or are in a therapeutic group with other drugs with multiple brands. Drugs on F2 are subject to the provisions of the Act relating to statutory price reductions, price disclosure and guarantee of supply. Allocation to F1 or F2 is determined by legislative instrument.
 2. Combination Drugs are not allocated to any formulary.
 3. The category 'Other' includes extemporaneously prepared items.
- * Excludes Section 100 prescriptions supplied through Remote Area Aboriginal Health Services.

PBS Expenditure and Prescriptions 2016-17

Table 14(a): Top 20 Responsible Persons by Total Cost, 2016-17

Section 85 only, including Drs Bag, excluding under co-payment prescriptions

Rank	Responsible Person	PBS Subsidised Prescriptions	Government Cost	Patient Contribution***	Total Cost*	Derived Ex-Manufacturer Sales**
1	GILEAD SCIENCES PTY LIMITED	67,639	\$ 1,432,629,242	\$ 1,070,308	\$ 1,433,699,550	\$ 1,397,698,332
2	NOVARTIS PHARMACEUTICALS AUSTRALIA PTY LIMITED	3,101,926	\$ 745,307,039	\$ 29,546,312	\$ 774,853,351	\$ 692,975,531
3	PFIZER AUSTRALIA PTY LTD	12,814,142	\$ 558,682,080	\$ 104,424,916	\$ 663,106,995	\$ 489,734,089
4	ALPHAPHARM PTY LTD	30,635,318	\$ 428,770,807	\$ 163,381,636	\$ 592,152,444	\$ 240,614,048
5	ASTRAZENECA PTY LTD	12,691,322	\$ 421,022,080	\$ 112,633,142	\$ 533,655,222	\$ 370,834,923
6	MERCK SHARP & DOHME (AUSTRALIA) PTY LTD	8,000,731	\$ 395,933,838	\$ 90,919,900	\$ 486,853,738	\$ 375,314,040
7	APOTEX PTY LTD	28,054,445	\$ 335,102,583	\$ 144,041,674	\$ 479,144,257	\$ 161,605,106
8	BAYER AUSTRALIA LTD	2,890,284	\$ 426,781,461	\$ 34,051,155	\$ 460,832,616	\$ 394,525,999
9	BRISTOL-MYERS SQUIBB AUSTRALIA PTY LTD	1,312,358	\$ 425,078,221	\$ 14,604,849	\$ 439,683,070	\$ 406,060,074
10	ABBVIE PTY LTD	234,330	\$ 385,562,231	\$ 5,624,356	\$ 391,186,587	\$ 361,661,088
11	SANOFI-AVENTIS AUSTRALIA PTY LTD	9,131,430	\$ 321,114,363	\$ 55,431,214	\$ 376,545,577	\$ 256,779,074
12	JANSSEN-CILAG PTY LTD	2,108,918	\$ 312,804,723	\$ 18,003,552	\$ 330,808,274	\$ 284,906,343
13	GLAXOSMITHKLINE AUSTRALIA PTY LTD	5,416,530	\$ 207,190,928	\$ 64,695,575	\$ 271,886,502	\$ 200,036,894
14	BOEHRINGER INGELHEIM PTY LTD	6,100,656	\$ 208,828,767	\$ 46,810,139	\$ 255,638,906	\$ 178,192,788
15	SANDOZ PTY LTD	13,252,234	\$ 176,577,082	\$ 73,336,270	\$ 249,913,351	\$ 98,836,208
16	MUNDIPHARMA PTY LIMITED	4,519,932	\$ 183,514,448	\$ 33,892,782	\$ 217,407,231	\$ 142,115,015
17	ARROW PHARMA PTY LTD	10,901,158	\$ 128,339,261	\$ 56,588,409	\$ 184,927,670	\$ 63,258,387
18	AMGEN AUSTRALIA PTY LIMITED	514,210	\$ 146,600,538	\$ 5,781,126	\$ 152,381,664	\$ 134,971,939
19	NOVO NORDISK PHARMACEUTICALS PTY LIMITED	1,018,123	\$ 139,826,182	\$ 11,219,163	\$ 151,045,345	\$ 129,655,327
20	ASPEN PHARMA PTY LTD	4,693,783	\$ 70,914,793	\$ 25,515,112	\$ 96,429,905	\$ 34,367,670

* Total Cost includes cost to the patient and cost to the government for PBS Subsidised Prescriptions.

** Derived Ex-Manufacturer Sales is derived by subtracting the Wholesale Margin amount from the Price to Pharmacist for Dispensed Quantity (per script).

*** The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

PBS Expenditure and Prescriptions 2016-17

Table 14(b): Top 20 Responsible Persons by PBS Subsidised Prescriptions, 2016-17

Section 85 only, including Drs Bag, excluding under co-payment prescriptions

Rank	Responsible Person	PBS Subsidised Prescriptions	Government Cost	Patient Contribution***	Total Cost*	Derived Ex- Manufacturer Sales **
1	ALPHAPHARM PTY LTD	30,635,318	\$ 428,770,807	\$ 163,381,636	\$ 592,152,444	\$ 240,614,048
2	APOTEX PTY LTD	28,054,445	\$ 335,102,583	\$ 144,041,674	\$ 479,144,257	\$ 161,605,106
3	SANDOZ PTY LTD	13,252,234	\$ 176,577,082	\$ 73,336,270	\$ 249,913,351	\$ 98,836,208
4	PFIZER AUSTRALIA PTY LTD	12,814,142	\$ 558,682,080	\$ 104,424,916	\$ 663,106,995	\$ 489,734,089
5	ASTRAZENECA PTY LTD	12,691,322	\$ 421,022,080	\$ 112,633,142	\$ 533,655,222	\$ 370,834,923
6	ARROW PHARMA PTY LTD	10,901,158	\$ 128,339,261	\$ 56,588,409	\$ 184,927,670	\$ 63,258,387
7	SANOFI-AVENTIS AUSTRALIA PTY LTD	9,131,430	\$ 321,114,363	\$ 55,431,214	\$ 376,545,577	\$ 256,779,074
8	MERCK SHARP & DOHME (AUSTRALIA) PTY LTD	8,000,731	\$ 395,933,838	\$ 90,919,900	\$ 486,853,738	\$ 375,314,040
9	BOEHRINGER INGELHEIM PTY LTD	6,100,656	\$ 208,828,767	\$ 46,810,139	\$ 255,638,906	\$ 178,192,788
10	GLAXOSMITHKLINE AUSTRALIA PTY LTD	5,416,530	\$ 207,190,928	\$ 64,695,575	\$ 271,886,502	\$ 200,036,894
11	ASPEN PHARMA PTY LTD	4,693,783	\$ 70,914,793	\$ 25,515,112	\$ 96,429,905	\$ 34,367,670
12	ASPEN PHARMACARE AUSTRALIA PTY LIMITED	4,524,112	\$ 66,802,705	\$ 25,443,741	\$ 92,246,446	\$ 38,940,021
13	MUNDIPHARMA PTY LIMITED	4,519,932	\$ 183,514,448	\$ 33,892,782	\$ 217,407,231	\$ 142,115,015
14	SERVIER LABORATORIES (AUST.) PTY LTD	3,549,652	\$ 47,766,096	\$ 18,524,226	\$ 66,290,322	\$ 26,947,888
15	FAWNS AND MCALLAN PROPRIETARY LIMITED	3,180,910	\$ 41,722,253	\$ 15,416,016	\$ 57,138,269	\$ 20,653,152
16	NOVARTIS PHARMACEUTICALS AUSTRALIA PTY LIMITED	3,101,926	\$ 745,307,039	\$ 29,546,312	\$ 774,853,351	\$ 692,975,531
17	BAYER AUSTRALIA LTD	2,890,284	\$ 426,781,461	\$ 34,051,155	\$ 460,832,616	\$ 394,525,999
18	AMNEAL PHARMACEUTICALS PTY LTD	2,623,735	\$ 33,449,160	\$ 13,770,466	\$ 47,219,626	\$ 17,221,915
19	BGP PRODUCTS PTY LTD	2,363,889	\$ 55,769,325	\$ 17,857,885	\$ 73,627,210	\$ 45,146,026
20	JANSSEN-CILAG PTY LTD	2,108,918	\$ 312,804,723	\$ 18,003,552	\$ 330,808,274	\$ 284,906,343

* Total Cost includes cost to the patient and cost to the government for PBS Subsidised Prescriptions.

** Derived Ex-Manufacturer Sales is derived by subtracting the Wholesale Margin amount from the Price to Pharmacist for Dispensed Quantity (per script).

*** The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

Table 15: Number of Approved Community Pharmacies and Dispensing Doctors, 30 June 2017

Pharmacy State	Number of Community Pharmacies	Number of Dispensing Doctors
NSW	1,864	4
Vic	1,346	1
Qld	1,130	1
SA	454	1
WA	611	3
Tas	149	3
NT	36	-
ACT	75	-
Total	5,665	13

Table 16: PBS Special Patient Contributions, 2016-17

Section 85 only, excluding Drs Bag and under co-payment prescriptions

	2016-17
Number of brands listed on the PBS(a)	5,271
Number of brands with a premium(a)	346
% of brands with a premium	6.6%
Average brand premium	\$4.23
Weighted average brand premium(b)	\$3.19
Brand premium range	\$0.19 To \$35.30
Prescriptions (millions) dispensed with a brand premium	29.9
Prescriptions (millions) dispensed at the benchmark level (c)	107.2
% of prescriptions dispensed at benchmark level	78.2%

Notes:

(a) A brand is defined as a unique combination of 'brand name' and 'form and strength' as at June 2017 PBS Schedule.(b) Weighted average brand premium is calculated by:

total premium value / total prescriptions with a premium = weighted average brand premium

(c) Includes only items where at least one brand is listed with a premium.

Table 17(a) PBS/RPBS prescriptions dispensed by Community Pharmacies, 2016-17

Section 85 and Section 100 prescriptions dispensed by Community Pharmacies, excluding Drs Bag and under co-payment prescriptions

Prescription Type	Concessional		General		RPBS		Total	
	Prescriptions	%	Prescriptions	%	Prescriptions	%	Prescriptions	%
Discounted	52,476,246	29%	4,227,830	28%	1,653,279	20%	58,357,355	29%
Non-Discounted	126,411,787	71%	10,938,972	72%	6,754,068	80%	144,104,827	71%
Grand Total	178,888,033	100%	15,166,802	100%	8,407,347	100%	202,462,182	100%

Table 17(b) PBS/RPBS prescriptions by Discount Range dispensed by Community Pharmacies, 2016-17

Section 85 and Section 100 prescriptions dispensed by Community Pharmacies, excluding Drs Bag and under co-payment prescriptions

Discount Range	Concessional		General		RPBS		Total	
	Prescriptions	%	Prescriptions	%	Prescriptions	%	Prescriptions	%
\$1.00	50,692,069	96.6%	4,111,193	97.2%	1,590,409	96.2%	56,393,671	96.6%
0.50 - LT \$1.00	339,159	0.6%	30,232	0.7%	8,910	0.5%	378,301	0.6%
LT 50c	760,903	1.4%	37,147	0.9%	30,298	1.8%	828,348	1.4%
Other	684,115	1.3%	49,258	1.2%	23,662	1.4%	757,035	1.3%
Grand Total	52,476,246	100.0%	4,227,830	100.0%	1,653,279	100.0%	58,357,355	100.0%

PBS Expenditure and Prescriptions 2016-17

Table 18(a): PBS/RPBS Continued Dispensing Medicines Prescriptions by Dispensing Pharmacy State/Territory, 2016-17
Section 85 only, including Drs Bag and under co-payment prescriptions

Drug Name	NSW	Vic	Qld	SA	WA	Tas	NT	ACT	National
ATORVASTATIN	847	693	50	178	227	171	4	276	2,446
FLUVASTATIN	1	-	-	-	-	-	-	1	2
LEVONORGESTREL	34	22	6	8	21	3	-	7	101
LEVONORGESTREL + ETHINYLOESTRADIOL	677	721	121	221	210	298	7	159	2,414
NORETHISTERONE	6	3	-	1	1	2	-	-	13
NORETHISTERONE + ETHINYLOESTRADIOL	73	46	13	18	8	33	-	24	215
NORETHISTERONE + MESTRANOL	2	10	1	1	5	-	-	-	19
PRAVASTATIN	69	41	2	6	12	13	-	18	161
ROSUVASTATIN	901	630	51	159	157	199	1	181	2,279
SIMVASTATIN	207	171	11	43	52	57	-	68	609
Grand Total	2,817	2,337	255	635	693	776	12	734	8,259

Table 18(b): PBS/RPBS Continued Dispensing Medicines Government Cost by Dispensing Pharmacy State/Territory, 2016-17
Section 85 only, including Drs Bag and under co-payment prescriptions

Drug Name	NSW	Vic	Qld	SA	WA	Tas	NT	ACT	National
ATORVASTATIN	\$ 5,033	\$ 4,118	\$ 229	\$ 1,087	\$ 1,241	\$ 1,125	\$ 23	\$ 1,358	\$ 14,215
FLUVASTATIN	\$ 39	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 39	\$ 78
LEVONORGESTREL	\$ 99	\$ 67	\$ 27	\$ -	\$ 46	\$ 27	\$ -	\$ -	\$ 265
LEVONORGESTREL + ETHINYLOESTRADIOL	\$ 1,826	\$ 1,978	\$ 233	\$ 378	\$ 288	\$ 991	\$ -	\$ 265	\$ 5,959
NORETHISTERONE	\$ 26	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 26
NORETHISTERONE + ETHINYLOESTRADIOL	\$ 209	\$ 78	\$ 39	\$ 26	\$ 13	\$ 143	\$ -	\$ 39	\$ 548
NORETHISTERONE + MESTRANOL	\$ -	\$ 52	\$ 13	\$ 13	\$ 13	\$ -	\$ -	\$ -	\$ 91
PRAVASTATIN	\$ 516	\$ 338	\$ 14	\$ 48	\$ 69	\$ 90	\$ -	\$ 110	\$ 1,186
ROSUVASTATIN	\$ 7,398	\$ 5,325	\$ 318	\$ 1,160	\$ 1,255	\$ 2,039	\$ -	\$ 1,161	\$ 18,656
SIMVASTATIN	\$ 1,207	\$ 1,016	\$ 65	\$ 228	\$ 315	\$ 372	\$ -	\$ 295	\$ 3,499
Grand Total	\$ 16,353	\$ 12,973	\$ 938	\$ 2,941	\$ 3,240	\$ 4,788	\$ 23	\$ 3,267	\$ 44,523

Table 19: Remuneration for Community Pharmacies and Friendly Societies¹, 2016-17
Section 85 and Section 100, including Drs Bag, excluding under co-payment prescriptions

Pharmacy remuneration recognises the cost to the approved pharmacist for the purchase of the medicines; the administration, handling and storage costs entailed in dispensing medicines by the pharmacy (including associated infrastructure costs); and a pharmacist's specialised skills in dispensing the medicines.

	Expenses for PBS and RPBS Prescriptions	2015-16	2016-17	Change	Percentage Change
Price to Pharmacists					
	Ex-Manufacturer Price	\$6,676,550,692	\$7,302,004,813	\$625,454,120	9.4%
	Wholesale Mark-up	\$381,563,997	\$371,882,787	-\$9,681,210	-2.5%
	Sub total	\$7,058,114,689	\$7,673,887,600	\$615,772,911	8.7%
Administration, Handling and Storage Costs					
	AHI fee*	\$851,328,291	\$841,276,633	-\$10,051,658	-1.2%
	Sub total	\$851,328,291	\$841,276,633	-\$10,051,658	-1.2%
	*Administration, Handling and Infrastructure fee, formerly known as Pharmacy Mark-up				
Pharmacist's Specialised Skills in Dispensing the Medicines					
	Dispensing Fee	\$1,461,984,336	\$1,418,211,935	-\$43,772,401	-3.0%
	Dangerous Drug Fee	\$23,684,601	\$24,368,596	\$683,995	2.9%
	Wastage	\$2,999,399	\$3,638,035	\$638,636	21.3%
	Container Fee	\$291,536	\$312,864	\$21,328	7.3%
	Sub total	\$1,488,959,872	\$1,446,531,430	-\$42,428,442	-2.8%
Other					
	Premium Free Dispensing Incentive	\$108,641,538	\$120,068,983	\$11,427,444	10.5%
	Electronic Prescription Fee ²	\$9,038,357	\$8,762,413	-\$275,944	-3.1%
	Sub total	\$117,679,895	\$128,831,396	\$11,151,501	9.5%
	Total³	\$9,516,082,746	\$10,090,527,058	\$574,444,311	6.0%

Summary of Medicines, Wholesalers, and Pharmacy Costs

Medicines cost	\$6,676,550,692	\$7,302,004,813	\$625,454,120	9.4%
Wholesale cost	\$381,563,997	\$371,882,787	-\$9,681,210	-2.5%
Pharmacy cost	\$2,457,968,057	\$2,416,639,458	-\$41,328,599	-1.7%
Total	\$9,516,082,746	\$10,090,527,058	\$574,444,311	6.0%

1. Table 19 is for PBS and RPBS prescriptions claimed by community pharmacies and friendly societies for both Section 85 and some Section 100 items. It includes Government and patient contributions.

It does not include:

- * Efficient Funding of Chemotherapy (EFC);
- * hospital PBS claims for s85 items (as the report's focus is on community pharmacy);
- * some private hospital HSD claims; and
- * most public hospital HSD claims.

Given what data is and is not included, this table may not be directly comparable to earlier tables in this publication.

2. The Electronic Prescription Fee (EPF) is listed as a programme under 6CPA.

3. Health's 2016-17 Annual Report lists the administered expenses for pharmaceutical benefits as \$12.058 billion. The difference between that figure and the total figure above is attributable to:

- * the annual report captures all s85 and s100 accrued expenses (including all HSDs and EFC), while the above data captures all s85 and some s100 data for community pharmacy and friendly societies only (it excludes a number of smaller s100 programmes, for example growth hormone and Remote Area Aboriginal Health Services Programme).
- * the annual report data is based on accrual figures, whilst the above data is cash basis;
- * the annual report does not include patient contributions;
- * the annual report data does not include the Premium Free Dispensing Incentive (PFDI) or EPF;
- * the annual report is PBS only and does not include RPBS, whereas the above data includes RPBS; and

Table 20: CPA Professional Pharmacy Programmes Expenditure, 2016-17

Under the Sixth CPA there were a range of professional programmes and services delivered by community pharmacy and pharmacists to support the primary health care needs of consumers. The following table details the funds spent on these programmes under CPA in 2016-17 by relevant categories.

Program Type	Actual Expenditure
Rural Pharmacy Maintenance Allowance	\$15,681,187
Rural Pharmacy Workforce Program	\$5,499,321
Medication Management services	\$64,135,250
Medication Adherence services	\$64,423,967
Aboriginal & Torres Strait Islander programs	\$6,254,625
Pharmacy Guild administration fees	\$5,796,996
Programs Total	\$161,791,346

Notes:

1. For the Programs administration arrangements for 2016-17 (administered by the Pharmacy Guild), the total funding provided to the Pharmacy Guild was \$161,791,346 (accrual figure). Of this, \$5,796,996 was provided to the Pharmacy Guild for the purpose of Pharmacy Guild administration fees. This means the Pharmacy Guild administration fees was 3.58% of the total funds.
2. The Electronic Prescription Fees (EPF) program expenditure is separately reported in Table 19 of the report.
3. Rural Pharmacy Workforce Program, Medication Management services, Medication Adherence Services and Aboriginal and Torres Strait Islander Programs are made up of multiple elements, as per the following tables.

Medication Management services consist of the following elements:	Actual Expenditure
Diabetes Medscheck and Medscheck	\$12,518,813
Residential Medication Management Review (RMMR)	\$16,000,000
Home Medicines Review (HMR)	\$15,999,910
Clinical Interventions by pharmacists (Pharmacy Practice Incentives)	\$19,616,527
Program Total	\$64,135,250

Medication Adherence services consist of the following elements:	Actual Expenditure
Dose Administration Aids (Pharmacy Practice Incentives)	\$58,241,967
Staged Supply (Pharmacy Practice Incentives)	\$6,182,000
Program Total	\$64,423,967

Aboriginal & Torres Strait Islander Programs consist of the following elements:	Actual Expenditure
Workforce (scholarships)	\$180,000
Workforce (traineeships)	\$160,000
Supporting s100 Remote Aboriginal Area Health Services (RAAHS)	\$3,402,142
Quality Use of Medicines Maximised for Aboriginal and Torres Strait Islander people (QUMAX)	\$2,512,483
Program Total	\$6,254,625

Rural Pharmacy Workforce Program consists of the following elements:	Actual Expenditure
Rural Pharmacist Pre-Reg Inc Allowance Pharmacy - Intern Training Allowance	\$175,000
Emergency Locum Service	\$350,000
Undergraduate Scholarship Internship Pharmacy - Student Placement	\$675,000
Undergraduate Pharmacy-Scholarship Scheme	\$1,200,000
CPE - Continuing Professional Education Allowance	\$420,000
Pharmacy - Rural Administration Support	\$470,000
Rural Pharmacy - Mentor Scheme	\$50,000
Post Intern Incentive Allowance	\$151,667
Undergraduate Scholarship Internship - Intern Incentive Allowance	\$1,166,667
RPLO	\$840,988
Program Total	\$5,499,321

Table 21: Actual Costs of Major Components of CPA*, 2016-17

Component	Expenditure
Pharmacy remuneration	\$ 2,416,639,458
Wholesale remuneration	\$ 371,882,787
Professional programmes	\$ 161,791,346
Community Services Obligation (CSO)	\$ 195,220,000
Total	\$ 3,145,533,591

* The current Community Pharmacy Agreement is the 6th CPA.

NOTES:

1. Details on how the above figures were identified are provided in the accompanying data tables. The above summary figures should be read in conjunction with the notes provided against each data table.
2. Professional programmes and CSO figures are accrual based, as the data used to identify the amounts are based on SAP records, which is an accrual based system.
3. The pharmacy remuneration figure is on a cash basis, as the data used to identify this amount was based on the Line by Line (LBL) data set Health receives from Human Services. It was not possible to use the SAP data (accrual basis) for this component, as SAP data does not provide the breakdown between medicine cost and pharmacy remuneration cost elements, whereas the LBL does.

Table 22: Community Services Obligation (CSO) Expenditure, 2016-17

Component	Expenditure
CSO funding pool	\$ 193,924,614
CSO admin	\$ 1,295,386
Total	\$ 195,220,000

The CSO for pharmaceutical wholesalers helps to ensure there are arrangements in place for all Australians to have access to PBS medicines, via their community pharmacy, in a timely manner.

Administration of the CSO funding pool is conducted by the Australian Healthcare Associates under contract to the Department of Health.

PBS INFORMATION LINE REPORT, 2016-2017

The PBS Information Line, established in 1990, is an Australia-wide service which gives information on all aspects of the Pharmaceutical Benefits Scheme to the general public, health professionals, consumer groups, and to other Government Departments and agencies.

During the period 1st July 2016 – 30th June 2017, the information line received **7,399** calls. This was a decrease of 11.18% from the previous financial year, where 8,330 calls were received.

Conclusion	Number of calls	%
Satisfied	7,380	99.74%
Dissatisfied	17	0.23%
Abusive	2	0.03%
Total	7,399	100.00

Breakdown of calls by month:

Month	Number of calls	%
July 2016	672	9.08%
August 2016	747	10.10%
September 2016	616	8.33%
October 2016	644	8.70%
November 2016	756	10.22%
December 2016	541	7.31%
January 2017	642	8.68%
February 2017	606	8.19%
March 2017	563	7.61%
April 2017	443	5.99%
May 2017	623	8.42%
June 2017	546	7.38%
Total	7,399	100.00

Breakdown of calls by issue:

Issue	Number of calls	%
Pharmacy Item	5,732	77.47%
Safety Net Issue	3,315	44.80%

Breakdown of calls: Pharmacy item issue

Pharmacy Item Issue	Number of calls	%
Authority Prescriptions	1,021	17.81%
Claims/Processing	620	10.82%
Other	565	9.86%
Listing Status Query	493	8.60%
Availability	369	6.44%
Cost of Item to Patient	353	6.16%
Refund - Failure to show entitlement	224	3.91%
Prescription Rules	170	2.97%
Brand Price Premium	168	2.93%
Centrelink Conc. Card	149	2.60%
Non PBS - Medicare/DHS	147	2.56%
Eligibility for the PBS	145	2.53%
Prescriber/Dispenser Number	121	2.11%
Doctors Bag/Emergency Drug Supplies	90	1.57%
Section 100 items	90	1.57%
Restricted items	75	1.31%
Non PBS - Centrelink/DVA	72	1.26%
Private Prescriptions (non-PBS)	68	1.19%
PBS Website Enquiry	67	1.17%
Schedule	64	1.12%
Cost of Item to Gov't	56	0.98%
Taking & Sending Medicines Overseas	55	0.96%
Prescription Shopping	49	0.85%
PBAC	46	0.80%
Closing the Gap	43	0.75%
Deletion of Item	38	0.66%
Repeats (Reg 25)	36	0.63%
PBS Statistics	35	0.61%
C'th Seniors Health Care Card	32	0.56%
Schedule 8 Drugs	30	0.52%
Generic Medicines	27	0.47%
Price Disclosure	27	0.47%
Brand Substitution	26	0.45%
Regulation 24	24	0.42%
RPBS enquiry	19	0.33%
Public Hospitals and the PBS	18	0.31%
Therapeutic Group Premium	18	0.31%
Special Access Scheme	15	0.26%
Recip Health Care Agreements	14	0.24%
Private Hospitals and the PBS	12	0.21%
IME	11	0.19%
Patient Contribution	9	0.16%

PBS Expenditure and Prescriptions 2016-17

HMR/DMMR	8	0.14%
SN20DR	8	0.14%
Extemp Prepared Item	3	0.05%
Hospital Reforms	1	0.02%
Special Patient Contribution	1	0.02%
Budget 2015	0	0.00%
Norfolk Island Reforms	0	0.00%
Totals	5,732	100

Breakdown of calls: Safety net issue

Safety Net Issue	Number of calls	%
Thresholds	952	28.72%
Refund - Exceeded the SN Threshold	757	22.84%
General SN Query	651	19.64%
Recording Prescriptions	212	6.40%
SN Processing	182	5.49%
Stationery	137	4.13%
Recordable Value	112	3.38%
Period	66	1.99%
Families/Dependants	62	1.87%
Eligibility	61	1.84%
CombSafetyNet(separated couples)	33	1.00%
Joint Safety Net	31	0.94%
Lost Card/Supplementary Card	27	0.81%
Cross-Overs	17	0.51%
Change of Status	15	0.45%
Totals	3,315	100

National Diabetes Services Scheme (NDSS)

Since its establishment in 1987, Diabetes Australia (under Diabetes Australia Ltd) has assisted with the administration of the National Diabetes Services Scheme (NDSS) on behalf of the Australian Government. The current agreement runs from 1 July 2016 until 30 June 2020.

The NDSS is managed by the Department of Health through the Diabetes Products Section, in the Pharmacy and Insurance Branch of the Technology Assessment and Access Division.

The NDSS provides registrants with access to products and services that support the self-management of diabetes at prices subsidised by the Australian Government. Products include syringes and needles, insulin infusion pump consumables, and blood and urine testing strips, and are available through Access Points nationally. Access Points comprise community pharmacies and very small numbers of other entities, such as health centres, hospitals and aged care facilities. Since 1 April 2017, the NDSS has also provided fully subsidised continuous glucose monitoring products to eligible young Australians with Type 1 Diabetes, up to the age of 21 years.

Details of registrant numbers are as follows:

Number of persons with diabetes registered with NDSS						
Year	Insulin using	% change	Non insulin using	% change	Total	% change
1990-91	57,087		12,121		69,208	
1991-92	67,693	18.58%	19,479	60.70%	87,172	25.96%
1992-93	79,010	16.72%	29,476	51.32%	108,486	24.45%
1993-94	90,962	15.13%	42,643	44.67%	133,605	23.15%
1994-95	103,263	13.52%	58,300	36.72%	161,563	20.93%
1995-96	116,275	12.60%	76,772	31.68%	193,047	19.49%
1996-97	129,076	11.01%	98,810	28.71%	227,886	18.05%
1997-98	142,484	10.39%	128,162	29.71%	270,646	18.76%
1998-99	155,943	9.45%	161,678	26.15%	317,621	17.36%
1999-2000	169,306	8.57%	202,549	25.28%	371,855	17.08%
2000-01	182,327	7.69%	246,805	21.85%	429,132	15.40%
2001-02	195,294	7.11%	298,599	20.99%	493,893	15.09%
2002-03	207,632	6.32%	353,825	18.50%	561,457	13.68%
2003-04	219,718	5.82%	409,150	15.64%	628,868	12.01%
2004-05	231,563	5.39%	466,409	13.99%	697,972	10.99%
2005-06	243,023	4.95%	525,365	12.64%	768,388	10.09%
2006-07	255,482	5.13%	588,580	12.03%	844,062	9.85%
2007-08	275,527	7.85%	622,340	5.74%	897,867	6.37%
2008-09	289,940	5.23%	577,567	-7.19%	867,507	-3.37%
2009-10	303,768	7.69%	653,570	8.65%	957,338	8.35%
2010-11	329,142	8.35%	703,575	7.65%	1,032,717	7.87%
2011-12	325,360	-1.15%	712,261	12.35%	1,037,621	0.48%
2012-13	342,349	5.22%	744,511	4.53%	1,086,860	4.75%
2013-14	356,807	4.22%	776,605	4.31%	1,133,412	4.28%
2014-15	371,197	4.03%	804,983	3.65%	1,176,180	3.77%
2015-16	383,439	3.3%	827,812	2.84%	1,211,251	3%
2016-17	396,460	3.4%	859,610	3.8%	1,256,070	3.7%

National Diabetes Services Scheme Expenditure

Total NDSS expenditure for the 2016-17 financial year was \$243.5 million. From 2016-17, NDSS Registrant co-payments are now returned to Consolidated Revenue

PBS Expenditure and Prescriptions 2016-17

Table 23(a): Historical Pharmaceutical Benefits Scheme Prescriptions (1948-49 to 2016-17)

PRESCRIPTIONS	GENERAL	PENSIONER	CONC	S/NET	TOTAL	DRS BAG	TOTAL - ALL PRESCRIPTIONS
1948/49	280,719				280,719		280,719
1949/50	484,210				484,210		484,210
1950/51	3,758,622				3,758,622		3,758,622
1951/52	6,515,668	1,655,570			8,171,238		8,171,238
1952/53	6,853,937	2,766,947			9,620,884		9,620,884
1953/54	7,004,421	3,453,551			10,457,972		10,457,972
1954/55	9,201,387	4,418,633			13,620,020		13,620,020
1955/56	8,970,890	5,235,013			14,205,903		14,205,903
1956/57	9,045,439	5,580,946			14,626,385		14,626,385
1957/58	10,309,446	6,313,214			16,622,660		16,622,660
1958/59	13,253,168	6,821,578			20,074,746		20,074,746
1959/60	16,624,342	8,028,968			24,653,310		24,653,310
1960/61	20,489,065	10,727,570			31,216,635		31,216,635
1961/62	26,050,370	11,664,036			37,714,406		37,714,406
1962/63	29,517,810	12,674,230			42,192,040		42,192,040
1963/64	31,039,624	13,317,273			44,356,897		44,356,897
1964/65	33,714,429	13,841,372			47,555,801		47,555,801
1965/66	35,084,551	14,908,393			49,992,944		49,992,944
1966/67	36,750,907	16,936,435			53,687,342		53,687,342
1967/68	37,053,212	18,369,634			55,422,846		55,422,846
1968/69	40,453,366	19,954,471			60,407,837		60,407,837
1969/70	44,071,198	21,504,166			65,575,364		65,575,364
1970/71	48,971,406	22,515,117			71,486,523		71,486,523
1971/72	48,491,692	23,950,503			72,442,195		72,442,195
1972/73	49,115,497	25,560,576			74,676,073		74,676,073
1973/74	59,499,823	27,788,036			87,287,859		87,287,859
1974/75	67,350,637	30,323,662			97,674,299		97,674,299
1975/76	67,722,534	33,394,757			101,117,291		101,117,291
1976/77	56,099,277	33,606,128			89,705,405		89,705,405
1977/78	57,751,904	35,414,619			93,166,523		93,166,523
1978/79	53,553,036	39,409,489			92,962,525		92,962,525
1979/80	46,624,224	42,450,386			89,074,610		89,074,610
1980/81	47,619,120	46,778,057			94,397,177		94,397,177
1981/82	53,834,648	49,739,756			103,574,404		103,574,404
1982/83	50,078,929	52,529,929	2,931,462		105,540,320		105,540,320
1983/84	41,938,964	56,491,285	9,954,995		108,385,244		108,385,244
1984/85	50,690,275	60,069,806	10,068,817		120,828,898		120,828,898
1985/86	46,334,279	63,191,858	10,315,799		119,841,936		119,841,936
1986/87	28,762,909	64,243,148	9,755,680	2	102,761,737		102,761,737
1987/88	12,339,360	81,041,242	7,520,752	15,059,811	100,901,354		100,901,354
1988/89	14,078,934	78,283,599	8,223,231	11,925,271	100,585,764		100,585,764
1989/90	15,361,517	80,761,310	8,856,241	11,725,474	104,979,068		104,979,068
1990/91	10,608,974	36,868,817	36,588,405	11,675,164	95,741,360	558,899	96,300,259

Notes

- Dr's Bag prior to 90/91 included in General, from 90/91 included in miscellaneous expenditure
- For 90/91 Concessional includes 'old' (prior to 1/11/90) prescriptions and 'new' (post 1/11/90) concessional category
- Safety Net
- Prior to 90/91 S/net for Gen & Concess is included in pensioner. In 90/91 free s/net is in both pensioner and s/net categories

PBS Expenditure and Prescriptions 2016-17

Table 23(a): Historical Pharmaceutical Benefits Scheme Prescriptions (1948-49 to 2016-17) Continued

PRESCRIPTIONS	GENERAL				CONCESSIONAL			TOTAL PRESCRIPTIONS	DRS BAG	TOTAL- ALL PRESCRIPTIONS
	NSN	S/Net 1	S/NET 2	TOTAL	NSN	S/NET	TOTAL			
1991/92	8,266,835	2,340,145	1,092,314	11,699,294	67,331,793	14,428,608	81,760,401	93,459,695	660,459	94,120,154
1992/93	10,260,426	3,917,022	2,800,496	16,977,944	71,756,325	16,757,840	88,514,165	105,492,109	689,508	106,181,617
1993/94	11,451,148	4,259,245	3,087,943	18,798,336	77,536,126	18,003,354	95,539,480	114,337,816	704,227	115,042,043
1994/95	13,491,364	4,695,314	2,072	18,188,750	82,400,588	17,457,008	99,857,596	118,046,346	674,331	118,720,677
1995/96	14,212,731	5,488,957	52	19,701,740	85,604,215	18,898,907	104,503,122	124,204,862	683,420	124,888,282
1996/97	14,709,601	3,082,843	14	17,792,458	85,965,797	19,676,007	105,641,804	123,434,262	665,301	124,099,563
1997/98	14,087,393	3,945,591	17	18,033,001	86,389,807	20,060,505	106,450,312	124,483,313	628,496	125,111,809
1998/99	15,153,975	4,111,091		19,265,066	88,475,327	20,608,073	109,083,400	128,348,466	572,753	128,921,219
1999/00	16,296,703	3,928,760		20,225,463	94,281,872	23,078,282	117,360,154	137,585,617	496,306	138,081,923
2000/01	18,526,141	4,340,364		22,866,505	99,285,160	25,420,114	124,705,274	147,571,779	478,999	148,050,778
2001/02	19,292,104	4,813,038		24,105,142	102,018,211	28,406,603	130,424,814	154,529,956	448,283	154,978,239
2002/03	20,694,131	5,188,492		25,882,623	101,459,056	31,177,491	132,636,547	158,519,170	437,516	158,956,686
2003/04	22,443,338	5,544,618		27,987,956	104,619,866	32,827,303	137,447,169	165,435,125	426,976	165,862,101
2004/05	22,194,451	6,209,302		28,403,753	105,377,946	36,095,311	141,473,257	169,877,010	402,492	170,279,502
2005/06	20,917,523	5,910,828		26,828,351	105,152,486	35,945,690	141,098,176	167,926,527	396,088	168,322,615
2006/07	19,871,669	4,710,422		24,582,091	110,917,202	32,675,864	143,593,066	168,175,157	360,362	168,535,519
2007/08	19,607,454	4,553,340		24,160,794	113,118,234	33,680,813	146,799,047	170,959,841	336,182	171,296,023
2008-09	20,746,777	5,580,636		26,327,413	119,906,347	35,234,371	155,140,718	181,468,131	367,996	181,836,127
2009-10	21,226,750	4,763,435		25,990,185	122,832,364	34,756,644	157,589,008	183,579,193	332,344	183,911,537
2010-11	21,032,398	4,943,233		25,975,631	125,446,923	36,381,986	161,828,909	187,804,540	337,715	188,142,255
2011-12	21,239,413	4,820,643		26,060,056	130,441,952	38,046,697	168,488,649	194,548,705	324,424	194,873,129
2012-13	19,323,589	4,371,046		23,694,635	133,646,630	39,611,994	173,258,624	196,953,259	352,123	197,305,382
2013-14	18,050,307	4,052,529		22,102,836	145,340,393	42,009,011	187,349,404	209,452,240	363,763	209,816,003
2014-15	15,902,515	3,544,902		19,447,417	147,979,717	44,277,679	192,257,396	211,704,813	380,376	212,085,189
2015-16	13,770,978	3,180,897		16,951,875	146,529,394	44,119,861	190,649,255	207,601,130	388,859	207,989,989

New Series	GENERAL			CONCESSIONAL			TOTAL PBS	DRS BAG	MISC and S100	TOTAL - ALL PRESCRIPTIONS
	NSN	S/Net	TOTAL	NSN	S/Net	TOTAL				
2016-17	12,334,542	2,699,345	15,033,887	144,336,986	36,045,418	180,382,404	195,416,291	394,352	2,560,813	198,371,456

CONC: Concessional

S/NET: Safety Net

PENSIONER: Before 1 November 1990 pensioners received PBS drugs free of charge.

NSN: Non Safety Net

S/NET 1, S/NET 2: Between 1991 and 1993 there were 2 tiers in the general safety net. Some prescriptions supplied during this period were processed in 1994 or after and the two tier structure applied to these.

MISC and SECT 100: Section 100 programmes.

Note: From 2016-17, the data is reported by the date that a prescription was supplied. Prior to this, prescriptions were reported by the date that they were processed by the Department of Human Services.

PBS Expenditure and Prescriptions 2016-17

Table 23(b): Historical Pharmaceutical Benefits Scheme Expenditure (1948-49 to 2016-17)

GOVERNMENT EXPENDITURE	-\$-					HOSP & MISC	TOTAL GOVT COST	PATIENT CONTRIBUTION		TOTAL COST PRESCRIPTIONS	TOTAL with S.100 & Misc	
YEAR	GEN	CONC	PENS	SAFETY NET	SUB TOTAL			GEN	CON	TOTAL		
1948/49	132,536				132,536	165,538	298,074			-	132,536	298,074
1949/50	346,682				346,682	262,696	609,378			-	346,682	609,378
1950/51	5,453,558				5,453,558	406,768	5,860,326			-	5,453,558	5,860,326
1951/52	13,424,294		715,264		14,139,558	1,230,536	15,370,094			-	14,139,558	15,370,094
1952/53	12,399,568		1,457,316		13,856,884	573,734	14,430,618			-	13,856,884	14,430,618
1953/54	14,320,372		2,021,560		16,341,932	2,116,894	18,458,826			-	16,341,932	18,458,826
1954/55	16,303,940		2,589,672		18,893,612	2,585,322	21,478,934			-	18,893,612	21,478,934
1955/56	18,061,092		3,015,920		21,077,012	2,697,858	23,774,870			-	21,077,012	23,774,870
1956/57	17,171,670		3,586,200		20,757,870	2,675,776	23,433,646			-	20,757,870	23,433,646
1957/58	22,826,484		4,246,490		27,072,974	2,995,004	30,067,978			-	27,072,974	30,067,978
1958/59	33,112,570		5,034,746		38,147,316	3,798,278	41,945,594			-	38,147,316	41,945,594
1959/60	36,714,806		7,148,446		43,863,252	4,808,090	48,671,342			1,890,756	45,754,008	50,562,098
1960/61	34,282,496		14,676,698		48,959,194	6,803,248	55,762,442	10,324,740		59,283,934	66,087,182	66,087,182
1961/62	44,632,488		18,194,996		62,827,484	7,552,282	70,379,766	13,007,776		75,835,260	83,387,542	83,387,542
1962/63	47,093,026		19,830,750		66,923,776	9,986,380	76,910,158	14,742,448		81,666,224	91,652,606	91,652,606
1963/64	46,460,998		20,601,714		67,062,712	11,775,958	78,838,670	15,573,804		82,636,516	94,412,474	94,412,474
1964/65	48,929,748		21,564,420		70,494,168	11,708,442	82,202,610	16,841,354		87,335,522	99,043,964	99,043,964
1965/66	53,078,046		24,071,127		77,149,173	14,634,501	91,783,674	17,481,228		94,630,401	109,264,902	109,264,902
1966/67	56,655,939		29,280,268		85,936,207	15,344,592	101,280,799	18,347,036		104,283,243	119,627,835	119,627,835
1967/68	56,800,249		32,115,335		88,915,584	16,218,859	105,134,443	18,504,345		107,419,929	123,638,788	123,638,788
1968/69	64,024,983		36,609,257		100,634,240	17,739,118	118,373,358	20,129,402		120,763,642	138,502,760	138,502,760
1969/70	73,227,887		41,068,702		114,296,589	22,421,727	136,718,316	21,941,691		136,238,280	158,660,007	158,660,007
1970/71	88,176,385		45,180,856		133,357,241	26,917,666	160,274,907	24,384,028		157,741,269	184,658,935	184,658,935
1971/72	90,061,869		52,005,350		142,067,219	31,201,229	173,268,448	35,466,642		177,533,861	208,735,090	208,735,090
1972/73	87,431,438		58,139,459		145,570,897	32,061,691	177,632,588	48,640,243		194,211,140	226,272,831	226,272,831
1973/74	108,066,351		66,802,821		174,869,172	43,426,672	218,295,844	59,015,335		233,884,507	277,311,179	277,311,179
1974/75	131,341,320		80,586,986		211,928,306	50,368,781	262,297,087	66,827,987		278,756,288	329,125,069	329,125,069
1975/76	149,033,245		107,317,318		256,350,563	27,490,706	283,841,269	95,244,660		351,595,223	379,085,929	379,085,929
1976/77	111,077,507		115,201,775		226,279,282	8,623,582	234,902,864	111,676,421		337,955,703	346,579,285	346,579,285
1977/78	118,303,375		127,911,837		246,215,212	9,832,410	256,047,622	115,025,169		361,240,381	371,072,791	371,072,791
1978/79	110,425,438		151,125,681		261,551,119	9,767,502	271,318,621	129,540,759		391,091,878	400,859,380	400,859,380
1979/80	101,185,503		166,361,113		267,546,616	7,088,452	274,635,068	123,418,168		390,964,784	398,053,236	398,053,236
1980/81	107,903,558		191,043,798		298,947,356	10,267,063	309,214,419	129,923,272		428,870,628	439,137,691	439,137,691
1981/82	139,547,856		239,894,493		379,442,349	11,377,241	390,819,590	157,957,635		537,399,984	548,777,225	548,777,225
1982/83	131,773,044	11,100,973	272,707,495		415,581,512	14,685,428	430,266,940	170,617,530	5,882,844	176,500,374	592,081,886	606,767,314
1983/84	114,638,367	39,276,732	317,819,660		471,734,759	17,490,165	489,224,924	166,043,447	19,975,026	186,018,473	657,753,232	675,243,397
1984/85	142,439,672	43,266,712	356,213,948		541,920,332	17,877,162	559,797,494	201,142,242	20,208,116	221,350,358	763,270,690	781,147,852
1985/86	138,365,148	50,172,930	408,026,507		596,564,585	19,258,116	615,822,701	222,286,396	20,715,057	243,001,453	839,566,038	858,824,154
1986/87	140,571,611	59,738,152	514,236,037	12	714,545,800	23,457,302	738,003,102	167,130,307	22,048,299	189,178,606	903,724,406	927,181,708
1987/88	111,740,361	51,574,897	747,536,316	159,418,168	910,851,574	35,612,019	946,463,593	117,938,301	18,839,286	136,777,587	1,047,629,161	1,083,241,180
1988/89	132,040,607	63,272,252	795,027,196	138,531,290	990,340,055	33,194,842	1,023,534,897	147,704,171	20,603,194	168,307,365	1,158,647,420	1,191,842,262
1989/90	170,039,203	74,757,555	890,753,297	150,064,548	1,135,550,055	43,852,385	1,179,402,440	162,587,554	22,174,539	184,762,093	1,320,312,148	1,364,164,533
1990/91	157,783,001	342,720,328	428,743,821	580,709,870	1,094,463,443	64,798,247	1,159,261,690	132,120,868	91,672,986	223,793,854	1,318,257,297	1,383,055,544

Note -Free Pensioner category removed from 1 Nov 90, \$2.50 copayment and free safety net introduced for all Concessionals
 -Dr's Bag prior to 90/91 included in General
 -For Gen & Conc prior to 90/91 is included in Pensioner
 -For 90/91 S/net includes both pre & post 1/11/90 free Snet
 -Gen S/net 1 included in Concness in 90/91
 -Gen S/net 2 (free) 1 Jan 91 to 31 Dec 93

Table 23(b): Historical Pharmaceutical Benefits Scheme Expenditure (1948-49 to 2016-17) Continued

GOVERNMENT EXPENDITURE	-\$-				CONC - NSN		TOTAL CONC	TOTAL FOR PBS	MISC and SECT 100	TOTAL GOVT EXP
	GENERAL-NSN	GEN S/Net 1	GEN S/Net 2	TOTAL GEN	CONC - NSN	CONC S/Net				
1991/92	160,765,548	36,400,482	18,911,584	216,077,614	708,413,833	195,000,082	903,413,915	1,119,491,529	100,877,826	1,220,369,355
1992/93	188,270,160	65,845,466	53,077,875	307,193,500	844,972,301	251,249,539	1,096,221,840	1,403,415,340	101,552,426	1,504,967,766
1993/94	224,675,364	78,832,510	63,861,452	367,369,326	1,019,651,580	297,597,894	1,317,249,474	1,684,618,800	116,696,888	1,801,315,688
1994/95	290,765,883	93,406,668	38,565	384,211,116	1,194,999,580	302,502,892	1,497,502,472	1,881,713,588	109,621,215	1,991,334,803
1995/96	343,025,066	118,655,085	785	461,680,936	1,369,432,585	360,130,508	1,729,563,093	2,191,244,029	135,473,133	2,326,717,162
1996/97	392,246,135	72,831,781	210	465,078,126	1,465,657,637	401,814,359	1,867,471,996	2,332,550,122	205,545,012	2,538,095,134
1997/98	411,856,192	98,613,376	465	510,470,033	1,576,058,096	439,989,321	2,016,047,417	2,526,517,450	258,950,240	2,785,467,690
1998/99	469,042,094	106,618,491	-	575,660,585	1,739,535,268	467,079,112	2,206,614,380	2,782,274,965	287,469,135	3,069,744,100
1999/00	521,018,128	107,012,848	-	628,030,976	2,000,636,597	547,829,734	2,548,466,331	3,176,497,307	311,727,262	3,488,224,569
2000/01	662,099,200	128,173,886	-	790,273,086	2,359,650,038	660,303,947	3,019,953,985	3,810,227,071	347,901,802	4,158,128,873
2001/02	691,204,687	148,498,520	-	839,703,207	2,569,555,585	778,411,796	3,347,967,381	4,187,670,588	396,386,682	4,584,057,270

PATIENT CONTRIBUTION -\$- **TOTAL COST**

PBS Expenditure and Prescriptions 2016-17

	GENERAL-NSN	GEN S/Net 1	GEN S/Net 2	TOTAL GEN	CONC - NSN	CONC S/Net	TOTAL CONC	TOTAL FOR PBS	TOTAL FOR PRESCRIPTIONS	MISC and SECT 100	TOTAL
1991/92	128,988,053	6,043,066		135,031,119	173,201,117		173,201,117	308,232,236	1,427,723,765	100,877,826	1,528,601,591
1992/93	162,967,769	10,202,578		173,170,347	186,726,902		186,726,902	359,897,249	1,763,312,589	101,552,426	1,864,865,015
1993/94	183,012,475	11,074,025		194,086,500	201,596,301		201,596,301	395,682,801	2,080,301,601	116,696,888	2,196,998,489
1994/95	218,094,751	12,207,816		230,302,567	214,241,512		214,241,512	444,544,079	2,326,257,667	109,621,215	2,435,878,882
1995/96	237,239,817	14,278,699		251,518,516	226,583,554		226,583,554	478,102,070	2,669,346,099	135,473,133	2,804,819,232
1996/97	269,715,066	8,375,980		278,091,046	252,104,590		252,104,590	530,195,636	2,862,745,758	205,545,012	3,068,290,770
1997/98	281,739,252	12,625,016		294,364,268	276,440,026		276,440,026	570,804,294	3,097,321,744	258,950,240	3,356,271,984
1998/99	305,064,052	13,155,417		318,219,469	283,117,963		283,117,963	601,337,432	3,383,612,397	287,469,135	3,671,081,532
1999/00	333,003,549	12,584,337		345,587,886	306,183,001		306,183,001	651,770,887	3,828,268,194	311,727,262	4,139,995,456
2000/01	392,432,536	14,353,837		406,786,373	337,379,028		337,379,028	744,165,401	4,554,392,472	347,901,802	4,902,294,274
2001/02	426,974,621	16,864,336		443,838,957	362,237,529		362,237,529	806,076,486	4,993,747,074	396,386,682	5,390,133,756
DOCTOR'S BAG - \$ - (included in miscellaneous from 90/91)											
1990/91		12,255,895									
1991/92		14,514,725									
1992/93		16,082,655									
1993/94		16,679,933									
1994/95		15,674,643									
1995/96		16,202,098									
1996/97		15,769,173									
1997/98		14,953,823									
1998/99		13,370,491									
1999/00		10,754,395									
2000/01		10,343,534									
2001/02		9,803,682									

note- from 91/92 all figures are sourced from Department of Human Services (DHS) processing where available
-miscellaneous and section 100 expenditure sourced from Department of Health and DHS payments

S/NET 1, S/NET 2: Between 1991 and 1993 there were 2 tiers in the general safety net. Some prescriptions supplied during this period were processed in 1994 or after and the two tier structure applied to these.

CONC: Concessional

S/Net: Safety Net

GEN: General

NSN: Non Safety Net

MISC and SECT 100: Drugs provided through special programs and hospitals; Section 100 drugs.

HOSP & MISC: Drugs provided through special programs and hospitals; Section 100 drugs.

PENS: Before 1 November 1990 pensioners received PBS drugs free of charge.

Table 23(b): Historical Pharmaceutical Benefits Scheme Expenditure (1948-49 to 2016-17) Continued

GOVERNMENT EXPENDITURE - \$-											
	GENERAL-NSN	GEN S/Net	TOTAL GEN	CONC - NSN	CONC S/Net	TOTAL CONC	TOTAL FOR PBS	MISC and SECT 100	TOTAL GOVT EXP		
2002/03	\$747,049,026	\$169,693,390	\$916,742,416	\$2,741,874,040	\$907,119,434	\$3,648,993,474	\$4,565,735,890	\$477,352,298	\$5,043,088,188		
2003/04	\$824,130,608	\$190,682,979	\$1,014,813,587	\$2,972,331,634	\$1,004,522,779	\$3,976,854,413	\$4,991,668,000	\$570,500,000	\$5,562,168,000		
2004/05	\$850,690,906	\$222,668,220	\$1,073,359,125	\$3,077,033,801	\$1,145,497,231	\$4,222,531,032	\$5,295,890,157	\$668,500,000	\$5,964,390,157		
2005/06	\$850,095,680	\$216,246,563	\$1,066,342,242	\$3,145,480,431	\$1,172,502,111	\$4,317,982,542	\$5,384,324,784	\$764,000,000	\$6,148,324,784		
2006/07	\$890,275,536	\$174,127,771	\$1,064,403,307	\$3,333,875,949	\$1,067,478,074	\$4,401,354,023	\$5,465,757,330	\$886,500,000	\$6,352,257,330		
2007/08	\$1,039,451,749	\$173,499,550	\$1,212,951,299	\$3,561,294,283	\$1,137,925,393	\$4,699,219,676	\$5,912,170,974	\$975,500,000	\$6,887,670,974		
2008/09	\$1,220,279,806	\$217,487,483	\$1,437,767,290	\$3,909,584,010	\$1,216,050,241	\$5,125,634,250	\$6,563,401,540	\$1,081,400,000	\$7,644,801,540		
2009/10	\$1,339,182,210	\$199,599,002	\$1,538,781,212	\$4,220,391,341	\$1,259,719,602	\$5,480,110,943	\$7,018,892,155	\$1,232,400,000	\$8,251,292,155		
2010-11	\$1,412,781,352	\$211,944,918	\$1,624,726,270	\$4,367,739,898	\$1,330,682,636	\$5,698,422,533	\$7,323,148,803	\$1,335,500,000	\$8,658,648,803		
2011-12	\$1,453,773,280	\$208,167,009	\$1,661,940,288	\$4,476,104,435	\$1,390,159,396	\$5,866,263,831	\$7,528,204,119	\$1,473,700,000	\$9,001,904,119		
2012-13	\$1,339,654,102	\$169,213,844	\$1,508,867,945	\$4,209,086,581	\$1,351,536,398	\$5,560,622,979	\$7,069,490,924	\$1,812,600,000	\$8,882,090,924		
PATIENT CONTRIBUTION - \$-											
	GENERAL-NSN	GEN S/Net	TOTAL GEN	CONC - NSN	CONC S/Net	TOTAL CONC	TOTAL FOR PBS	TOTAL - FOR PRESCRIPTIONS	MISC and SECT 100	TOTAL	
2002/03	\$470,306,937	\$18,698,099	\$489,005,036	\$370,426,183	-	\$370,426,183	\$859,431,219	\$5,425,167,109	\$477,352,298	\$5,902,519,407	
2003/04	\$524,763,848	\$20,538,514	\$545,302,362	\$392,513,143	-	\$392,513,143	\$937,815,505	\$5,929,483,505	\$570,500,000	\$6,499,983,505	
2004/05	\$572,963,103	\$23,742,733	\$596,705,836	\$443,930,641	-	\$443,930,641	\$1,040,636,477	\$6,336,526,634	\$668,500,000	\$7,005,026,634	
2005/06	\$606,897,345	\$27,199,070	\$634,096,415	\$489,173,277	-	\$489,173,277	\$1,123,269,692	\$6,507,594,476	\$764,000,000	\$7,271,594,476	
2006/07	\$596,483,266	\$22,154,622	\$618,637,888	\$532,682,972	-	\$532,682,972	\$1,151,320,859	\$6,617,078,189	\$886,500,000	\$7,503,578,189	
2007/08	\$607,183,393	\$22,323,024	\$629,506,417	\$559,962,883	-	\$559,962,883	\$1,189,469,300	\$7,101,640,274	\$975,500,000	\$8,077,140,274	
2008/09	\$663,449,571	\$27,928,829	\$691,378,400	\$617,378,323	-	\$617,378,323	\$1,308,756,723	\$7,872,158,263	\$1,081,400,000	\$8,953,558,263	
2009/10	\$701,961,714	\$25,253,391	\$727,215,106	\$656,949,638	-	\$656,949,638	\$1,384,164,743	\$8,403,056,898	\$1,232,400,000	\$9,635,456,898	
2010-11	\$707,968,006	\$26,706,262	\$734,674,267	\$689,108,592	-	\$689,108,592	\$1,423,782,860	\$8,746,931,663	\$1,335,500,000	\$10,082,431,663	
2011-12	\$735,994,339	\$27,003,502	\$762,997,841	\$742,139,779	-	\$742,139,779	\$1,505,137,620	\$9,033,341,739	\$1,473,700,000	\$10,507,041,739	
2012-13	\$689,036,554	\$25,352,649	\$714,389,203	\$781,002,893	-	\$781,002,893	\$1,495,392,096	\$8,564,883,021	\$1,812,600,000	\$10,377,483,021	
Doctor's Bag - \$ - (included in miscellaneous from 90/91)											
2002/03		\$9,510,606									
2003/04		\$9,408,669									
2004/05		\$9,365,803									
2005/06		\$10,063,803									

note- from 91/92 all figures are sourced from Department of Human Services (DHS) processing where available

PBS Expenditure and Prescriptions 2016-17

2006/07	\$10,698,205	-miscellaneous and section 100 expenditure sourced from Department of Health and DHS payments
2007/08	\$13,468,779	
2008/09	\$14,533,302	
2009/10	\$13,571,776	
2010-11	\$14,228,520	
2011-12	\$12,974,506	
2012-13	\$14,755,085	

S/NET 1, S/NET 2: Between 1991 and 1993 there were 2 tiers in the general safety net. Some prescriptions supplied during this period were processed in 1994 or after and the two tier structure applied to these.

CONC: Concessional
S/Net: Safety Net
GEN: General
NSN: Non Safety Net

MISC and SECT 100: Drugs provided through special programs and hospitals; Section 100 drugs.
HOSP & MISC: Drugs provided through special programs and hospitals; Section 100 drugs.
PENS: Before 1 November 1990 pensioners received PBS drugs free of charge.

Table 23(b): Pharmaceutical Benefits Scheme History - Government Expenditure & Patient Contribution, 1948-49 to 2016-17 Continued

GOVERNMENT EXPENDITURE - \$-										
	GENERAL-NSN	GEN S/Net	TOTAL GEN	CONC - NSN	CONC S/Net	TOTAL CONC	TOTAL FOR PBS	MISC and SECT 100	TOTAL GOVT EXP	
2013-14	\$1,429,860,300	\$154,692,449	\$1,584,552,749	\$4,319,414,670	\$1,388,583,542	\$5,707,998,212	\$7,292,550,961	\$2,033,900,000	\$9,326,450,961	
2014-15	\$1,463,256,600	\$129,523,975	\$1,592,780,575	\$4,123,482,128	\$1,380,416,342	\$5,503,898,470	\$7,096,679,044	\$2,183,101,118	\$9,279,780,162	
2015-16	\$1,785,357,915	\$118,821,879	\$1,904,179,793	\$4,630,980,302	\$1,413,858,158	\$6,044,838,460	\$7,949,018,254	\$2,752,825,107	\$10,701,843,361	
New Series	GENERAL-NSN	GEN S/Net	TOTAL GEN	CONC - NSN	CONC S/Net	TOTAL CONC	TOTAL PBS	DRS BAG	MISC and S100	TOTAL GOVT EXP
2016-17	\$2,088,188,915	\$103,984,977	\$2,192,173,892	\$5,315,606,905	\$1,204,716,252	\$6,520,323,157	\$8,712,497,049	\$16,718,674	\$3,043,936,194	\$11,773,151,917
PATIENT CONTRIBUTION - \$-										
	GENERAL-NSN	GEN S/Net	TOTAL GEN	CONC - NSN	CONC S/Net	TOTAL CONC	TOTAL FOR PBS	TOTAL COST TOTAL - FOR PRESCRIPTIONS	MISC and SECT 100	TOTAL
2013-14	\$656,913,329	\$23,915,012	\$680,828,341	\$864,226,399	-	\$864,226,399	\$1,545,054,740	\$8,837,605,701	\$2,033,900,000	\$10,871,505,701
2014-15	\$567,399,905	\$21,021,090	\$588,420,995	\$877,483,279	-	\$877,483,279	\$1,465,904,274	\$8,562,583,318	\$2,183,101,118	\$10,745,684,436
2015-16	\$494,124,051	\$19,115,443	\$513,239,494	\$880,965,644	-	\$880,965,644	\$1,394,205,138	\$9,343,223,391	\$2,752,825,107	\$12,096,048,498
New Series	GENERAL-NSN	GEN S/Net	TOTAL GEN	CONC - NSN	CONC S/Net	TOTAL CONC	TOTAL PBS	TOTAL COST *	MISC and S100	OTAL GOVT EXP **
2016-17	\$444,029,285	\$16,448,625	\$460,477,909	880,418,081	\$0	\$880,418,081	\$1,340,895,990	\$10,053,393,039	\$38,361,124	\$13,152,409,031
TOTAL COST *	Total cost for Section85 (Patient payment + government benefit)									
TOTAL GOVT EXP **	Total PBS Expenditure, Section 85, Section 100 and Drs Bag (Patient payment + government benefit)									
Doctor's Bag - \$ - (included in miscellaneous from 90/91)										
2013-14	\$16,009,408									
2014-15	\$16,340,036									
2015-16	\$15,887,150									
2016-17	\$16,718,674									

Notes:

From 2016-17, the data is reported by the date that a prescription was supplied. Prior to this, Government expenditure and patient contributions were reported by the date that the prescriptions were processed by the Department of Human Services.

From 1991-92 all figures are sourced from Department of Human Services (DHS) processing where available

Miscellaneous and section 100 expenditure sourced from Department of Health and DHS payments

S/NET 1, S/NET 2: Between 1991 and 1993 there were 2 tiers in the general safety net. Some prescriptions supplied during this period were processed in 1994 or after and the two tier structure applied to these.

CONC: Concessional
S/Net: Safety Net
GEN: General
NSN: Non Safety Net

MISC and SECT 100: Section 100 programmes, other ungrouped expenditure
HOSP & MISC: Drugs provided through special programs and hospitals; Section 100 drugs.
PENS: Before 1 November 1990 pensioners received PBS drugs free of charge.